NF	B-GP
-	I-GP
kappaΒ	I-GP
-	I-GP
inducing	I-GP
kinase	I-GP
regulates	O
stem	O
cell	O
phenotype	O
in	O
breast	B-DS
cancer	I-DS

Breast	B-DS
cancer	I-DS
stem	O
cells	O
(	O
BCSCs	O
)	O
overexpress	O
components	O
of	O
the	O
Nuclear	B-GP
factor	I-GP
-	I-GP
kappa	I-GP
B	I-GP
(	O
NF	B-GP
-	I-GP
κB	I-GP
)	O
signaling	O
cascade	O
and	O
consequently	O
display	O
high	O
NF	B-GP
-	I-GP
κB	I-GP
activity	O
levels	O
.	O

Breast	B-DS
cancer	I-DS
cell	O
lines	O
with	O
high	O
proportion	O
of	O
CSCs	O
exhibit	O
high	O
NF	B-GP
-	I-GP
κB	I-GP
-	I-GP
inducing	I-GP
kinase	I-GP
(	O
NIK	B-GP
)	O
expression	O
.	O

The	O
role	O
of	O
NIK	B-GP
in	O
the	O
phenotype	O
of	O
cancer	B-DS
stem	O
cell	O
regulation	O
is	O
poorly	O
understood	O
.	O

Expression	O
of	O
NIK	B-GP
was	O
analyzed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
in	O
BCSCs	O
.	O

NIK	B-GP
levels	O
were	O
manipulated	O
through	O
transfection	O
of	O
specific	O
shRNAs	O
or	O
an	O
expression	O
vector	O
.	O

The	O
effect	O
of	O
NIK	B-GP
in	O
the	O
cancer	B-DS
stem	O
cell	O
properties	O
was	O
assessed	O
by	O
mammosphere	O
formation	O
,	O
mice	B-OG
xenografts	O
and	O
stem	O
markers	O
expression	O
.	O

BCSCs	O
expressed	O
higher	O
levels	O
of	O
NIK	B-GP
and	O
its	O
inhibition	O
through	O
small	O
hairpin	O
(	O
shRNA	O
),	O
reduced	O
the	O
expression	O
of	O
CSC	O
markers	O
and	O
impaired	O
clonogenicity	O
and	O
tumorigenesis	O
.	O

Genome	O
-	O
wide	O
expression	O
analyses	O
suggested	O
that	O
NIK	B-GP
acts	O
on	O
ERK1	B-GP
/	O
2	O
pathway	O
to	O
exert	O
its	O
activity	O
.	O

In	O
addition	O
,	O
forced	O
expression	O
of	O
NIK	B-GP
increased	O
the	O
BCSC	O
population	O
and	O
enhanced	O
breast	B-DS
cancer	I-DS
cell	O
tumorigenicity	O
.	O

The	O
in	O
vivo	O
relevance	O
of	O
these	O
results	O
is	O
further	O
supported	O
by	O
a	O
tissue	O
microarray	O
of	O
breast	B-DS
cancer	I-DS
samples	O
in	O
which	O
we	O
observed	O
correlated	O
expression	O
of	O
Aldehyde	B-GP
dehydrogenase	I-GP
(	O
ALDH	B-GP
)	O
and	O
NIK	B-GP
protein	O
.	O

Our	O
results	O
support	O
the	O
essential	O
involvement	O
of	O
NIK	B-GP
in	O
BCSC	O
phenotypic	O
regulation	O
via	O
ERK1	B-GP
/	O
2	O
and	O
NF	B-GP
-	I-GP
κB	I-GP
.	O

Several	O
reports	O
have	O
shown	O
that	O
tumors	B-DS
contain	O
subpopulations	O
of	O
Cancer	B-DS
Stem	O
Cells	O
(	O
CSCs	O
)	O
that	O
can	O
initiate	O
and	O
sustain	O
tumor	B-DS
growth1	O
.	O

CSCs	O
self	O
-	O
renew	O
by	O
generating	O
unlimited	O
copies	O
and	O
also	O
give	O
rise	O
to	O
mature	O
non	O
-	O
stem	O
cell	O
progeny	O
through	O
differentiation	O
,	O
thus	O
producing	O
phenotypically	O
different	O
cells12	O
.	O

Breast	B-DS
cancer	I-DS
stem	O
cells	O
are	O
classically	O
defined	O
by	O
CD44	B-GP
(	O
Cluster	B-GP
of	I-GP
Differentiation	I-GP
antigen	I-GP
-	I-GP
44	I-GP
)	O
positive	O
and	O
low	O
or	O
absent	O
levels	O
of	O
CD24	B-GP
(	O
Cluster	B-GP
of	I-GP
Differentiation	I-GP
antigen	I-GP
-	I-GP
24	I-GP
)	O
expression	O
(	O
CD44	B-GP
+/	O
CD24	B-GP
−/	O
low	O
).	O

Xenotransplant	O
assays	O
have	O
revealed	O
that	O
as	O
few	O
as	O
100	O
cells	O
with	O
the	O
CD44	B-GP
+/	O
CD24	B-GP
−/	O
low	O
phenotype	O
can	O
form	O
tumors	B-DS
in	O
immunodeficient	O
mice3	O
.	O

Breast	B-DS
Cancer	I-DS
Stem	O
Cells	O
(	O
BCSCs	O
)	O
also	O
exhibit	O
high	O
levels	O
of	O
Wnt	B-GP
,	O
Notch	B-GP
,	O
Hedgehog	B-GP
,	O
JAK	B-GP
/	O
STAT	B-GP
and	O
Nuclear	B-GP
factor	I-GP
-	I-GP
kappa	I-GP
B	I-GP
(	O
NF	B-GP
-	I-GP
κB	I-GP
)	O
activity	O
;	O
these	O
pathways	O
regulate	O
self	O
-	O
renewal	O
and	O
differentiation	O
processes456	O
.	O

NF	B-GP
-	I-GP
κB	I-GP
refers	O
to	O
a	O
family	O
of	O
transcription	B-GP
factors	I-GP
that	O
control	O
the	O
expression	O
of	O
many	O
genes	O
related	O
to	O
immune	O
responses	O
,	O
survival	O
,	O
proliferation	O
,	O
angiogenesis	O
,	O
and	O
metastasis7	O
.	O

The	O
NF	B-GP
-	I-GP
κB	I-GP
family	O
consists	O
of	O
the	O
following	O
five	O
transcription	B-GP
factors	I-GP
:	O
RelA	B-GP
(	O
p65	B-GP
),	O
RelB	B-GP
,	O
c	B-GP
-	I-GP
Rel	I-GP
,	O
p100	B-GP
/	O
p52	B-GP
,	O
and	O
p105	B-GP
/	O
p50	B-GP
;	O
these	O
factors	O
can	O
homo	O
or	O
heterodimerize	O
to	O
allow	O
DNA	O
binding	O
and	O
activate	O
transcription	O
.	O

Two	O
main	O
signaling	O
pathways	O
,	O
the	O
canonical	O
,	O
and	O
non	O
-	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathways	O
activate	O
NF	B-GP
-	I-GP
κB	I-GP
;	O
both	O
pathways	O
rely	O
on	O
signals	O
that	O
induce	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
inhibitors	O
(	O
IκB	B-GP
proteins	O
).	O

After	O
degradation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
inhibitors	O
,	O
the	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
is	O
activated	O
by	O
translocation	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
dimers	O
.	O

Canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
mainly	O
induces	O
the	O
translocation	O
of	O
the	O
p50	B-GP
:	O
p65	B-GP
dimer	O
,	O
while	O
the	O
non	O
-	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
primarily	O
triggers	O
p52	B-GP
:	O
RelB	B-GP
dimer	O
translocation	O
through	O
NF	B-GP
-	I-GP
κB	I-GP
-	I-GP
inducing	I-GP
kinase	I-GP
(	O
NIK	B-GP
)	O
89	O
.	O

NIK	B-GP
,	O
a	O
MAP	B-GP
kinase	I-GP
kinase	I-GP
kinase	I-GP
(	O
MAP3K14	B-GP
)	O
protein	O
,	O
is	O
essential	O
for	O
the	O
activation	O
of	O
the	O
non	O
-	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
because	O
it	O
phosphorylates	O
IκB	B-GP
Kinase	I-GP
-	I-GP
α	I-GP
(	O
IKKα	B-GP
)	O
and	O
participates	O
in	O
the	O
processing	O
of	O
p10010	B-GP
.	O

NIK	B-GP
also	O
phosphorylates	O
IκB	B-GP
Kinase	I-GP
-	I-GP
β	I-GP
(	O
IKKβ	B-GP
)	O
and	O
activates	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway11	O
.	O

NIK	B-GP
is	O
involved	O
in	O
processes	O
such	O
as	O
cell	O
differentiation	O
,	O
development	O
,	O
and	O
embryogenesis	O
;	O
in	O
the	O
latter	O
,	O
NIK	B-GP
appears	O
to	O
play	O
a	O
role	O
in	O
pluripotent	O
embryonic	O
stem	O
cell	O
maintenance12	O
.	O

These	O
activities	O
of	O
NIK	B-GP
support	O
a	O
potential	O
role	O
in	O
the	O
regulation	O
of	O
stem	O
cell	O
behavior12131415	O
.	O

In	O
this	O
regard	O
,	O
mutant	O
mice	B-OG
with	O
defects	O
in	O
the	O
non	O
-	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
,	O
including	O
NIK	B-GP
,	O
display	O
abnormalities	O
in	O
mammary	O
gland	O
development161718	O
.	O

NIK	B-GP
is	O
frequently	O
overexpressed	O
in	O
basal	O
and	O
claudin	B-GP
-	O
low	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
,	O
and	O
its	O
overexpression	O
leads	O
to	O
constitutive	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
and	O
proliferation	O
in	O
these	O
tumor192021	O
.	O

Basal	O
and	O
claudin	B-GP
-	O
low	O
carcinomas	B-DS
are	O
mainly	O
estrogen	B-GP
receptor	I-GP
(	O
ER	B-GP
)-	O
negative	O
,	O
progesterone	B-GP
receptor	I-GP
(	O
PR	B-GP
)-	O
negative	O
,	O
and	O
human	B-GP
epidermal	I-GP
growth	I-GP
factor	I-GP
receptor	I-GP
2	I-GP
(	O
HER2	B-GP
)-	O
negative	O
(	O
triple	O
negative	O
).	O

Triple	O
negative	O
tumors	B-DS
are	O
more	O
aggressive	O
,	O
have	O
a	O
poor	O
prognosis	O
,	O
and	O
contain	O
higher	O
proportions	O
of	O
BCSCs	O
(	O
CD44	B-GP
+/	O
CD24	B-GP
−/	O
low	O
)	O
than	O
other	O
tumor	B-DS
subtypes2223	O
.	O

Recently	O
,	O
Zhang	O
et	O
al	O
.	O
observed	O
that	O
NIK	B-GP
-	O
IKKα	B-GP
regulates	O
HER2	B-GP
-	O
induced	O
mammary	O
tumorigenesis	O
by	O
promoting	O
the	O
nuclear	O
exclusion	O
of	O
p27	B-GP
/	O
Kip1	B-GP
,	O
thereby	O
supporting	O
the	O
proliferation	O
and	O
expansion	O
of	O
BCSCs	O
in	O
a	O
mouse	B-OG
tumorigenesis	O
model24	O
.	O

In	O
contrast	O
to	O
its	O
role	O
in	O
breast	B-DS
cancer	I-DS
tumorigenesis	O
,	O
information	O
about	O
the	O
role	O
of	O
NIK	B-GP
in	O
CSC	O
is	O
limited	O
.	O

The	O
aim	O
of	O
this	O
project	O
was	O
to	O
determine	O
the	O
role	O
of	O
NIK	B-GP
in	O
the	O
phenotype	O
of	O
BCSCs	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
NIK	B-GP
is	O
overexpressed	O
in	O
BCSCs	O
isolated	O
from	O
MCF7	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
.	O

By	O
disrupting	O
NIK	B-GP
expression	O
,	O
we	O
show	O
that	O
NIK	B-GP
inhibition	O
affects	O
the	O
number	O
of	O
BCSCs	O
and	O
concomitantly	O
reduces	O
the	O
expression	O
levels	O
of	O
Aldehyde	B-GP
Dehydrogrenase	I-GP
-	I-GP
1A1	I-GP
(	O
ALDH1A1	B-GP
),	O
NANOG	B-GP
,	O
SOX2	B-GP
(	O
SRY	B-GP
-	I-GP
BOX2	I-GP
),	O
and	O
Octamer	B-GP
-	I-GP
Binding	I-GP
Transcription	I-GP
Factor	I-GP
(	O
OCT4	B-GP
).	O

In	O
addition	O
,	O
we	O
found	O
that	O
Aldehyde	B-GP
Dehydrogenase	I-GP
1	I-GP
(	O
ALDH1	B-GP
)	O
is	O
co	O
-	O
expressed	O
with	O
NIK	B-GP
in	O
tumor	B-DS
cells	O
from	O
patients	O
with	O
breast	B-DS
cancer	I-DS
.	O

NIK	B-GP
inhibition	O
impaired	O
the	O
ability	O
of	O
cells	O
to	O
grow	O
tumors	B-DS
in	O
immunodeficient	O
mice	B-OG
.	O

In	O
support	O
of	O
these	O
results	O
,	O
we	O
also	O
observed	O
that	O
NIK	B-GP
overexpression	O
increased	O
the	O
proportion	O
of	O
CD44	B-GP
+/	O
CD24	B-GP
−/	O
low	O
cells	O
and	O
stem	O
cell	O
markers	O
in	O
MCF7	O
cells	O
.	O

Interestingly	O
,	O
microarray	O
data	O
revealed	O
that	O
NIK	B-GP
regulated	O
stem	O
cell	O
-	O
related	O
genes	O
through	O
the	O
Extracellular	B-GP
Signal	I-GP
-	I-GP
Regulates	I-GP
Kinases	I-GP
(	O
ERK	B-GP
)	O
pathway	O
.	O

Results	O

Isolation	O
of	O
BCSCs	O
Derived	O
from	O
Breast	B-DS
Cancer	I-DS
Cell	O
Lines	O

To	O
isolate	O
BCSCs	O
,	O
we	O
used	O
specific	O
antibodies	O
against	O
surface	O
markers	O
(	O
CD44	B-GP
,	O
CD24	B-GP
or	O
Epithelial	B-GP
Cell	I-GP
Adhesion	I-GP
Molecule	I-GP
(	O
ESA	B-GP
)	O
in	O
a	O
luminal	O
(	O
MCF7	O
)	O
and	O
a	O
triple	O
negative	O
(	O
MDA	O
-	O
MB	O
-	O
231	O
)	O
breast	B-DS
cancer	I-DS
cell	O
line	O
.	O

BCSCs	O
content	O
varies	O
greatly	O
among	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
and	O
breast	O
carcinomas252627	O
.	O

Triple	O
negative	O
tumors	B-DS
contain	O
large	O
numbers	O
of	O
CSCs	O
while	O
luminal	O
breast	B-DS
tumors	I-DS
have	O
lower	O
stem	O
cell	O
contents2223	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
MCF7	O
cell	O
line	O
has	O
a	O
low	O
percentage	O
of	O
BCSCs	O
(	O
CD44	B-GP
+/	O
CD24	B-GP
−/	O
low	O
cells	O
;	O
0	O
.	O
7	O
–	O
1	O
.	O
4	O
%;	O
Fig	O
.	O
1A	O
).	O

Since	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
line	O
exhibits	O
low	O
or	O
null	O
CD24	B-GP
expression	O
(	O
data	O
not	O
shown	O
),	O
we	O
used	O
CD44	B-GP
and	O
ESA	B-GP
to	O
detect	O
the	O
stem	O
cell	O
population	O
(	O
Fig	O
.	O
1B	O
).	O

Thus	O
,	O
we	O
determined	O
that	O
34	O
%	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
were	O
CD44	B-GP
+/	O
ESA	B-GP
+	O
cells	O
.	O

In	O
addition	O
,	O
we	O
isolated	O
a	O
high	O
ALDH	B-GP
activity	O
subpopulation	O
,	O
since	O
it	O
was	O
shown	O
previously	O
that	O
this	O
population	O
presents	O
phenotypic	O
and	O
functional	O
characteristics	O
of	O
BCSC28	O
.	O

Thus	O
,	O
we	O
determined	O
that	O
only	O
16	O
%	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
exhibit	O
ALDH	B-GP
activity	O
(	O
Supplementary	O
Fig	O
.	O

S1A	O
,	O
B	O
).	O

BCSCs	O
can	O
initiate	O
tumors	B-DS
and	O
drive	O
neoplastic	O
proliferation	O
.	O

To	O
verify	O
the	O
tumorigenic	O
potential	O
of	O
BCSCs	O
,	O
we	O
injected	O
BCSCs	O
and	O
non	O
-	O
BCSCs	O
into	O
immunodeficient	O
nu	B-OG
/	I-OG
nu	I-OG
mice	I-OG
.	O

MCF7	O
cells	O
with	O
the	O
CD44	B-GP
+/	O
CD24low	O
/−	O
phenotype	O
were	O
compared	O
with	O
CD44	B-GP
−/	O
CD24	B-GP
+	O
cells	O
.	O

After	O
120	O
days	O
,	O
all	O
mice	B-OG
inoculated	O
with	O
CD44	B-GP
+/	O
CD24	B-GP
/	O
low	O
/−	O
MCF7	O
cells	O
grew	O
visible	O
tumors	B-DS
,	O
unlike	O
CD44	B-GP
−/	O
CD24	B-GP
+	O
cells	O
(	O
Supplementary	O
Table	O
S1	O
).	O

Sorted	O
ESA	B-GP
+	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
were	O
able	O
to	O
form	O
tumors	B-DS
within	O
90	O
days	O
while	O
the	O
majority	O
of	O
mice	B-OG
inoculated	O
with	O
ESA	B-GP
−	O
did	O
not	O
form	O
tumors	B-DS
(	O
Supplementary	O
Table	O
S1	O
).	O

To	O
verify	O
their	O
clonogenic	O
potential	O
,	O
isolated	O
MCF7	O
BCSCs	O
and	O
non	O
-	O
BCSCs	O
were	O
seeded	O
on	O
soft	O
agar	O
plates	O
.	O

The	O
number	O
of	O
colonies	O
formed	O
by	O
CD44	B-GP
+/	O
CD24low	O
/−	O
cells	O
was	O
significantly	O
higher	O
than	O
those	O
formed	O
by	O
CD44	B-GP
−/	O
CD24	B-GP
+	O
(	O
818	O
vs	O
.	O
236	O
colonies	O
)	O
(	O
Fig	O
.	O
1C	O
).	O

In	O
addition	O
,	O
the	O
clonogenic	O
potential	O
of	O
sorted	O
MDA	O
-	O
MB	O
-	O
231	O
BCSCs	O
was	O
evaluated	O
in	O
limited	O
dilution	O
assays	O
,	O
which	O
revealed	O
that	O
the	O
CD44	B-GP
+/	O
ESA	B-GP
−	O
cells	O
were	O
more	O
clonogenic	O
than	O
the	O
CD44	B-GP
−/	O
ESA	B-GP
−	O
cells	O
(	O
6	O
colonies	O
vs	O
.	O
2	O
colonies	O
at	O
low	O
-	O
density	O
cell	O
dilution	O
)	O
(	O
Fig	O
.	O
1D	O
).	O

BCSCs	O
Express	O
Higher	O
Levels	O
of	O
NIK	B-GP

CSCs	O
express	O
high	O
levels	O
of	O
stem	O
cell	O
markers	O
,	O
which	O
contribute	O
to	O
their	O
self	O
-	O
renewal	O
properties2829	O
.	O

We	O
found	O
that	O
isolated	O
MCF7	O
CD44	B-GP
+/	O
CD24low	O
/−	O
cells	O
exhibited	O
higher	O
expression	O
levels	O
of	O
OCT4	B-GP
,	O
NANOG	B-GP
,	O
ALDH1A3	B-GP
,	O
ALDH1A3	B-GP
and	O
ALDH8A1	B-GP
compared	O
to	O
the	O
CD44	B-GP
−/	O
CD24	B-GP
+	O
subpopulation	O
(	O
Fig	O
.	O
1E	O
).	O

BCSCs	O
(	O
CD44	B-GP
+/	O
ESA	B-GP
+)	O
derived	O
from	O
the	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
line	O
,	O
also	O
expressed	O
higher	O
levels	O
of	O
some	O
stem	O
cell	O
markers	O
,	O
including	O
SOX2	B-GP
,	O
OCT4	B-GP
,	O
NANOG	B-GP
and	O
ALDH8A1	B-GP
compared	O
to	O
CD44	B-GP
−/	O
ESA	B-GP
−	O
cells	O
(	O
Fig	O
.	O
1F	O
).	O

NIK	B-GP
(	O
also	O
known	O
as	O
MAP3K14	B-GP
),	O
a	O
NF	B-GP
-	I-GP
κB	I-GP
activator	O
,	O
is	O
upregulated	O
in	O
basal	O
breast	B-DS
cancer	I-DS
cell	O
lines1920	O
,	O
which	O
are	O
enriched	O
in	O
CSCs22	O
.	O

For	O
this	O
reason	O
,	O
we	O
examined	O
the	O
levels	O
of	O
this	O
kinase	B-GP
in	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
claudin	B-GP
low	O
),	O
SKBR3	O
(	O
HER2	B-GP
+)	O
and	O
MCF7	O
(	O
luminal	O
)	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
and	O
found	O
that	O
as	O
expected	O
,	O
NIK	B-GP
is	O
highly	O
expressed	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
and	O
barely	O
detectable	O
in	O
MCF7	O
cells	O
(	O
Supplementary	O
Fig	O
.	O

S2	O
).	O

To	O
determine	O
if	O
NIK	B-GP
expression	O
in	O
BCSCs	O
was	O
up	O
-	O
regulated	O
,	O
we	O
examined	O
its	O
mRNA	O
levels	O
in	O
a	O
two	O
cell	O
lines	O
.	O
Figure	O
2A	O
shows	O
that	O
MCF7	O
BCSCs	O
expressed	O
higher	O
levels	O
of	O
NIK	B-GP
than	O
the	O
non	O
-	O
stem	O
cell	O
population	O
(	O
CD44	B-GP
−/	O
CD24	B-GP
+).	O

In	O
addition	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
BCSCs	O
also	O
exhibited	O
higher	O
levels	O
of	O
NIK	B-GP
when	O
compared	O
to	O
CD44	B-GP
−/	O
ESA	B-GP
−	O
cells	O
(	O
Fig	O
.	O
2B	O
);	O
furthermore	O
NIK	B-GP
is	O
highly	O
expressed	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
with	O
ALDH	B-GP
activity	O
(	O
Supplementary	O
Fig	O
.	O

S1B	O
).	O

These	O
results	O
prompted	O
us	O
to	O
investigate	O
the	O
role	O
of	O
NIK	B-GP
in	O
the	O
stem	O
phenotype	O
of	O
breast	B-DS
cancer	I-DS
.	O

NIK	B-GP
Inhibition	O
Reduces	O
the	O
BCSC	O
Population	O
and	O
Affects	O
CSC	O
Marker	O
Expression	O

We	O
next	O
investigated	O
the	O
effect	O
of	O
NIK	B-GP
inhibition	O
on	O
the	O
CSC	O
phenotype	O
.	O

We	O
generated	O
stable	O
MCF7	O
(	O
MCF7	O
-	O
shNIK	O
),	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
MDA231	O
-	O
shNIK	O
)	O
and	O
SKBR3	O
(	O
SKBR3	O
-	O
shNIK	O
)	O
cell	O
lines	O
with	O
two	O
different	O
small	O
hairpin	O
RNAs	O
(	O
shRNAs	O
).	O

RT	O
-	O
qPCR	O
analysis	O
showed	O
that	O
the	O
two	O
shRNAs	O
efficiently	O
reduced	O
NIK	B-GP
expression	O
in	O
MCF7	O
(	O
Fig	O
.	O
2C	O
),	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
Fig	O
.	O
2D	O
)	O
and	O
SKBR3	O
cells	O
(	O
Supplementary	O
Fig	O
.	O

S3A	O
)	O
in	O
comparison	O
with	O
MCF7	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
SKBR3	O
control	O
cells	O
,	O
respectively	O
.	O

In	O
MCF7	O
,	O
NIK	B-GP
deficiency	O
reduced	O
the	O
expression	O
of	O
SOX2	B-GP
,	O
OCT4	B-GP
,	O
NANOG	B-GP
,	O
ALDH1A3	B-GP
and	O
ALDH8A1	B-GP
.	O

Similar	O
results	O
were	O
obtained	O
employing	O
the	O
second	O
shRNA	O
against	O
NIK	B-GP
(	O
Fig	O
.	O
2E	O
).	O

In	O
further	O
support	O
of	O
these	O
findings	O
,	O
NIK	B-GP
inhibition	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
also	O
reduced	O
the	O
expression	O
of	O
SOX2	B-GP
,	O
OCT4	B-GP
,	O
ALDH1A3	B-GP
and	O
ALDH8A1	B-GP
(	O
Fig	O
.	O
2F	O
).	O

In	O
addition	O
,	O
NIK	B-GP
deficiency	O
also	O
reduced	O
the	O
expression	O
of	O
SOX2	B-GP
,	O
OCT4	B-GP
and	O
ALDH1A3	B-GP
in	O
SKBR3	O
cells	O
(	O
Supplementary	O
Fig	O
.	O

S3B	O
).	O

BCSCs	O
fraction	O
was	O
also	O
reduced	O
due	O
to	O
NIK	B-GP
inhibition	O
in	O
MCF7	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
lines	O
.	O

As	O
shown	O
in	O
Fig	O
.	O
3A	O
,	O
B	O
,	O
we	O
found	O
that	O
there	O
was	O
a	O
dramatic	O
reduction	O
in	O
the	O
BCSC	O
population	O
(	O
CD44	B-GP
+/	O
CD24	B-GP
−)	O
in	O
MCF7	O
-	O
shNIK1	B-GP
and	O
shNIK2	B-GP
.	O

Expression	O
of	O
cell	B-GP
surface	I-GP
proteins	I-GP
was	O
modified	O
due	O
to	O
NIK	B-GP
inhibition	O
(	O
Fig	O
.	O
3C	O
–	O
F	O
).	O

In	O
MCF7	O
cell	O
line	O
,	O
NIK	B-GP
inhibition	O
provoked	O
a	O
slightly	O
reduction	O
in	O
CD44	B-GP
levels	O
in	O
comparison	O
to	O
control	O
cells	O
(	O
Fig	O
.	O
3C	O
).	O

On	O
the	O
contrary	O
,	O
NIK	B-GP
inhibition	O
caused	O
a	O
10	O
%	O
increase	O
of	O
cells	O
expressing	O
CD24	B-GP
,	O
compared	O
with	O
the	O
control	O
cell	O
line	O
(	O
Fig	O
.	O
3D	O
).	O

To	O
further	O
support	O
these	O
results	O
,	O
we	O
found	O
that	O
NIK	B-GP
inhibition	O
also	O
decreased	O
the	O
CD44	B-GP
and	O
ESA	B-GP
positive	O
subpopulation	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
line	O
(	O
Fig	O
.	O
3E	O
,	O
F	O
).	O

NIK	B-GP
Depletion	O
Impacts	O
the	O
Clonogenic	O
and	O
Tumorigenic	O
Potential	O
of	O
Breast	B-DS
Cancer	I-DS
Cell	O
Lines	O

Because	O
our	O
results	O
show	O
that	O
NIK	B-GP
expression	O
is	O
associated	O
with	O
stem	O
cell	O
marker	O
expression	O
,	O
we	O
sought	O
to	O
determine	O
its	O
relevance	O
in	O
the	O
cancer	B-DS
stem	O
cell	O
phenotype	O
.	O
Figure	O
3G	O
shows	O
that	O
MCF7	O
deficient	O
NIK	B-GP
cells	O
formed	O
significantly	O
fewer	O
colonies	O
than	O
MCF7	O
-	O
shLuc	O
cells	O
.	O

The	O
clonogenic	O
potential	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
shNIK	O
cells	O
was	O
analyzed	O
in	O
limited	O
dilution	O
assays	O
.	O

MDA	O
-	O
MB	O
-	O
231	O
-	O
siNIK	O
cells	O
demonstrated	O
reduced	O
clonogenicity	O
compared	O
with	O
MDA	O
-	O
MB	O
-	O
231	O
-	O
siLuc	O
cells	O
(	O
Fig	O
.	O
3H	O
).	O

Similar	O
results	O
were	O
obtained	O
with	O
another	O
shRNA	O
against	O
NIK	B-GP
.	O

In	O
addition	O
,	O
MCF7	O
depleted	O
NIK	B-GP
cells	O
formed	O
lower	O
numbers	O
of	O
mammospheres	O
(	O
Fig	O
.	O
3I	O
).	O

Those	O
results	O
indicate	O
that	O
NIK	B-GP
depletion	O
impairs	O
the	O
clonogenic	O
potential	O
of	O
breast	B-DS
cancer	I-DS
cells	O
.	O

To	O
evaluate	O
the	O
tumorigenicity	O
of	O
NIK	B-GP
-	O
depleted	O
cells	O
,	O
we	O
inoculated	O
MDA231	O
-	O
shNIK	O
cells	O
carrying	O
a	O
luciferase	B-GP
reporter	O
in	O
nu	B-OG
/	I-OG
nu	I-OG
mice	I-OG
and	O
analyzed	O
the	O
tumor	B-DS
burden	O
six	O
weeks	O
later	O
.	O

The	O
results	O
showed	O
that	O
NIK	B-GP
inhibition	O
reduced	O
the	O
tumor	B-DS
burden	O
in	O
most	O
of	O
the	O
mice	B-OG
analyzed	O
.	O
Figure	O
3J	O
show	O
an	O
ELDA	O
analysis	O
of	O
inoculated	O
mice	B-OG
which	O
indicates	O
that	O
the	O
CSC	O
frequency	O
is	O
lower	O
in	O
MDA231	O
-	O
shNIK	O
cells	O
.	O

These	O
findings	O
support	O
the	O
idea	O
that	O
NIK	B-GP
could	O
be	O
essential	O
for	O
tumorigenic	O
abilities	O
of	O
BCSCs	O
.	O

Forced	O
NIK	B-GP
Expression	O
Increases	O
CSC	O
Marker	O
Expression	O
and	O
BCSC	O
Numbers	O

To	O
investigate	O
the	O
effects	O
of	O
NIK	B-GP
overexpression	O
on	O
the	O
stem	O
cell	O
phenotype	O
,	O
we	O
developed	O
stable	O
cell	O
lines	O
that	O
overexpressed	O
NIK	B-GP
(	O
MCF7	O
-	O
NIK	B-GP
+)	O
and	O
(	O
SKBR3	O
-	O
NIK	B-GP
+).	O

qPCR	O
analysis	O
showed	O
that	O
MCF7	O
-	O
NIK	B-GP
+	O
and	O
SKBR3	O
+	O
cells	O
expressed	O
60	O
fold	O
(	O
Fig	O
.	O
4A	O
)	O
and	O
4	O
fold	O
(	O
Supplementary	O
Fig	O
.	O
3A	O
)	O
higher	O
levels	O
of	O
NIK	B-GP
compared	O
with	O
MCF7	O
-	O
Mock	O
and	O
SKBR	O
-	O
Mock	O
cells	O
respectively	O
.	O

Our	O
results	O
showed	O
that	O
NIK	B-GP
overexpression	O
increased	O
the	O
expression	O
of	O
some	O
stem	O
cell	O
markers	O
.	O

In	O
MFC7	O
-	O
NIK	B-GP
+	O
cells	O
the	O
most	O
dramatic	O
changes	O
were	O
the	O
increase	O
in	O
ALDH1A3	B-GP
,	O
ALDH8A1	B-GP
,	O
and	O
SOX2	B-GP
(	O
Fig	O
.	O
4B	O
).	O

Overexpression	O
of	O
NIK	B-GP
in	O
SKBR3	O
also	O
increased	O
the	O
level	O
of	O
SOX2	B-GP
and	O
ALDH8A1	B-GP
(	O
Supplementary	O
Fig	O
.	O
3B	O
).	O

Forced	O
expression	O
of	O
NIK	B-GP
provokes	O
an	O
increment	O
of	O
CSC	O
fraction	O
in	O
MCF7	O
cells	O
(	O
Fig	O
.	O
4C	O
).	O

NIK	B-GP
overexpression	O
slightly	O
increases	O
the	O
expression	O
of	O
CD44	B-GP
(	O
Fig	O
.	O
4D	O
)	O
and	O
reduced	O
CD24	B-GP
expression	O
levels	O
(	O
Fig	O
.	O
4E	O
),	O
leading	O
to	O
an	O
increase	O
in	O
the	O
BCSC	O
population	O
(	O
CD44	B-GP
+/	O
CD24low	O
/−).	O

To	O
further	O
investigate	O
the	O
clonogenic	O
potential	O
of	O
MCF7	O
-	O
NIK	B-GP
+	O
cells	O
,	O
we	O
performed	O
soft	O
-	O
agar	O
clonogenicity	O
assays	O
.	O
Figure	O
4F	O
shows	O
that	O
NIK	B-GP
overexpression	O
increased	O
the	O
size	O
and	O
number	O
of	O
colonies	O
formed	O
by	O
MCF7	O
-	O
NIK	B-GP
+	O
cells	O
,	O
when	O
compared	O
with	O
MCF7	O
-	O
Mock	O
+	O
cells	O
.	O

We	O
also	O
found	O
that	O
NIK	B-GP
-	O
overexpressing	O
MCF7	O
cancer	B-DS
cells	O
developed	O
a	O
higher	O
number	O
of	O
mammospheres	O
and	O
the	O
sphere	O
-	O
forming	O
potential	O
is	O
sustained	O
even	O
after	O
a	O
second	O
passage	O
(	O
Fig	O
.	O
4G	O
).	O

To	O
further	O
support	O
these	O
results	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
SKBR3	O
-	O
NIK	B-GP
+	O
cells	O
to	O
form	O
mammospheres	O
,	O
Supplementary	O
Fig	O
.	O
3C	O
shows	O
that	O
NIK	B-GP
-	O
overexpressing	O
cells	O
form	O
a	O
higher	O
number	O
of	O
mammospheres	O
than	O
control	O
cells	O
.	O

To	O
determine	O
whether	O
forced	O
NIK	B-GP
expression	O
promotes	O
tumor	B-DS
growth	O
,	O
we	O
inoculated	O
nu	B-OG
/	I-OG
nu	I-OG
mice	I-OG
with	O
MCF7	O
-	O
NIK	B-GP
+	O
or	O
MCF7	O
-	O
Mock	O
cells	O
.	O

NIK	B-GP
overexpression	O
increased	O
the	O
number	O
of	O
tumors	B-DS
formed	O
by	O
MCF7	O
cells	O
.	O

ELDA	O
analysis	O
of	O
inoculated	O
mice	B-OG
showed	O
that	O
MCF7	O
-	O
NIK	B-GP
+	O
cells	O
have	O
a	O
higher	O
CSC	O
frequency	O
than	O
MCF7	O
-	O
Mock	O
cells	O
(	O
Fig	O
.	O
4H	O
).	O

In	O
addition	O
,	O
forced	O
expression	O
of	O
NIK	B-GP
in	O
SKBR3	O
cells	O
also	O
favored	O
tumor	B-DS
formation	O
and	O
a	O
higher	O
CSC	O
frequency	O
(	O
Supplementary	O
Fig	O
.	O

S3D	O
).	O

NIK	B-GP
Expression	O
Regulates	O
NF	B-GP
-	I-GP
κB	I-GP
Molecules	O

NIK	B-GP
is	O
an	O
essential	O
kinase	B-GP
that	O
induces	O
principally	O
non	O
-	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
by	O
phosphorylating	O
p100	B-GP
and	O
IKKα10	B-GP
.	O

Some	O
reports	O
have	O
shown	O
that	O
NIK	B-GP
can	O
also	O
phosphorylate	O
IKKβ	B-GP
and	O
activate	O
the	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway1130	O
.	O

To	O
verify	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
,	O
we	O
performed	O
a	O
reporter	O
gene	O
analysis	O
in	O
MCF7	O
cells	O
.	O

We	O
observed	O
that	O
NIK	B-GP
overexpression	O
dramatically	O
increased	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
while	O
NIK	B-GP
deficiency	O
impaired	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
when	O
compared	O
to	O
control	O
cells	O
(	O
Fig	O
.	O
5A	O
,	O
B	O
).	O

It	O
has	O
been	O
reported	O
that	O
NIK	B-GP
mediates	O
the	O
processing	O
of	O
p100	B-GP
to	O
p52	B-GP
and	O
promotes	O
the	O
nuclear	O
translocation	O
of	O
p52	B-GP
:	O
RelB	B-GP
dimer	O
.	O

In	O
agreement	O
with	O
this	O
,	O
we	O
found	O
that	O
NIK	B-GP
regulation	O
resulted	O
in	O
modulation	O
of	O
nuclear	O
p52	B-GP
.	O
Supplementary	O
Fig	O
.	O

S4A	O
,	O
B	O
shows	O
that	O
MCF7	O
-	O
NIK	B-GP
+	O
cells	O
presented	O
a	O
strong	O
nuclear	O
accumulation	O
of	O
p52	B-GP
,	O
as	O
opposed	O
to	O
MDA231	O
-	O
shNIK	O
cells	O
,	O
in	O
which	O
,	O
NIK	B-GP
inhibition	O
resulted	O
in	O
a	O
reduction	O
of	O
nuclear	O
p52	B-GP
(	O
Supplementary	O
Fig	O
.	O

S4C	O
,	O
D	O
).	O

To	O
determine	O
which	O
NF	B-GP
-	I-GP
κB	I-GP
molecules	O
are	O
involved	O
in	O
NIK	B-GP
-	O
mediated	O
regulation	O
of	O
CSC	O
marker	O
expression	O
,	O
we	O
performed	O
Western	O
blotting	O
and	O
immunofluorescence	O
analysis	O
of	O
key	O
NF	B-GP
-	I-GP
κB	I-GP
proteins	O
.	O

Western	O
blotting	O
assays	O
revealed	O
that	O
NIK	B-GP
increased	O
mainly	O
the	O
expression	O
of	O
p52	B-GP
,	O
RelB	B-GP
and	O
RelA	B-GP
/	O
p65	B-GP
(	O
Fig	O
.	O
5C	O
,	O
D	O
).	O

Immunofluorescence	O
analyses	O
showed	O
that	O
NIK	B-GP
overexpression	O
also	O
increased	O
the	O
expression	O
of	O
p52	B-GP
(	O
Fig	O
.	O
5E	O
),	O
RelB	B-GP
(	O
Fig	O
.	O
5F	O
)	O
and	O
p65	B-GP
(	O
Fig	O
.	O
5H	O
).	O

In	O
addition	O
,	O
NIK	B-GP
overexpression	O
also	O
increased	O
the	O
phosphorylation	O
of	O
p100	B-GP
/	O
p52	B-GP
(	O
Fig	O
.	O
5I	O
)	O
and	O
p65	B-GP
(	O
Fig	O
.	O
5J	O
).	O

Interestingly	O
,	O
p50	B-GP
levels	O
were	O
lower	O
in	O
MCF7	O
-	O
NIK	B-GP
+	O
cells	O
(	O
Fig	O
.	O
5G	O
).	O

NIK	B-GP
Expression	O
in	O
Patients	O
with	O
Breast	B-DS
Cancer	I-DS

Finally	O
,	O
we	O
determined	O
NIK	B-GP
levels	O
in	O
191	O
breast	B-DS
cancer	I-DS
tissue	O
samples	O
of	O
which	O
60	O
.	O
7	O
%	O
were	O
Luminal	O
,	O
13	O
.	O
6	O
%	O
were	O
triple	O
negative	O
and	O
9	O
.	O
4	O
%	O
were	O
HER2	B-GP
breast	B-DS
cancer	I-DS
subtype	O
(	O
Fig	O
.	O
6A	O
).	O

To	O
determine	O
whether	O
NIK	B-GP
expression	O
is	O
related	O
to	O
a	O
particular	O
breast	B-DS
cancer	I-DS
subtype	O
,	O
we	O
examine	O
NIK	B-GP
expression	O
by	O
immunohistochemistry	O
,	O
and	O
we	O
found	O
that	O
NIK	B-GP
expression	O
was	O
significantly	O
higher	O
in	O
HER2	B-GP
+	O
breast	B-DS
carcinomas	I-DS
(	O
Fig	O
.	O
6B	O
),	O
and	O
the	O
expression	O
of	O
NIK	B-GP
positively	O
correlated	O
with	O
HER2	B-GP
expression	O
levels	O
(	O
Fig	O
.	O
6C	O
).	O

We	O
also	O
found	O
that	O
Triple	O
Negative	O
carcinomas	B-DS
exhibited	O
the	O
lowest	O
expression	O
of	O
NIK	B-GP
,	O
contrary	O
to	O
previous	O
reports	O
of	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
(	O
Fig	O
.	O
6B	O
).	O

Tumor	B-DS
Samples	O
were	O
also	O
classified	O
as	O
grade	O
1	O
,	O
2	O
and	O
3	O
(	O
Fig	O
.	O
6D	O
).	O

Interestingly	O
,	O
we	O
observed	O
a	O
clear	O
positive	O
association	O
between	O
NIK	B-GP
and	O
tumor	B-DS
grade	O
(	O
Fig	O
.	O
6E	O
).	O

Immunohistochemistry	O
analysis	O
revealed	O
that	O
NIK	B-GP
was	O
expressed	O
in	O
79	O
.	O
5	O
%	O
(	O
152	O
)	O
breast	B-DS
cancer	I-DS
tissues	O
(	O
Fig	O
.	O
7A	O
).	O

To	O
support	O
our	O
previous	O
result	O
showing	O
that	O
NIK	B-GP
and	O
ALDH	B-GP
expression	O
are	O
correlated	O
,	O
we	O
analyzed	O
the	O
co	O
-	O
localization	O
of	O
both	O
proteins	O
in	O
these	O
samples	O
.	O

ALDH	B-GP
was	O
expressed	O
in	O
56	O
%	O
of	O
the	O
studied	O
cases	O
(	O
Fig	O
.	O
7B	O
),	O
of	O
which	O
97	O
%	O
also	O
expressed	O
NIK	B-GP
(	O
Fig	O
.	O
7C	O
).	O

Surprisingly	O
,	O
89	O
.	O
4	O
%	O
of	O
those	O
tumors	B-DS
presented	O
a	O
cellular	O
co	O
-	O
localization	O
of	O
both	O
proteins	O
as	O
shown	O
in	O
Fig	O
.	O
7D	O
.	O
Figure	O
7E	O
represents	O
tumors	B-DS
that	O
express	O
NIK	B-GP
and	O
ALDH	B-GP
in	O
different	O
cells	O
.	O
Figure	O
7F	O
–	O
H	O
represents	O
tumors	B-DS
lacking	O
either	O
NIK	B-GP
or	O
ALDH	B-GP
.	O

NIK	B-GP
altered	O
expression	O
affects	O
stem	O
cell	O
related	O
genes	O

To	O
elucidate	O
the	O
possible	O
mechanism	O
by	O
which	O
NIK	B-GP
affects	O
the	O
stem	O
cell	O
phenotype	O
,	O
we	O
performed	O
whole	O
-	O
genome	O
microarray	O
expression	O
analysis	O
of	O
NIK	B-GP
-	O
overexpressing	O
,	O
NIK	B-GP
-	O
deficient	O
,	O
and	O
MCF7	O
control	O
cells	O
.	O

As	O
expected	O
,	O
the	O
principal	O
component	O
analysis	O
divided	O
the	O
samples	O
into	O
three	O
groups	O
;	O
high	O
NIK	B-GP
expression	O
(	O
NIK	B-GP
+),	O
low	O
NIK	B-GP
expression	O
(	O
NIK	B-GP
−)	O
and	O
the	O
control	O
cells	O
(	O
Fig	O
.	O
8A	O
).	O

We	O
found	O
significant	O
gene	O
expression	O
differences	O
in	O
79	O
genes	O
in	O
MCF7	O
overexpressing	O
-	O
NIK	B-GP
cells	O
and	O
53	O
differential	O
expressed	O
genes	O
in	O
MCF7	O
deficient	O
NIK	B-GP
cells	O
(	O
Supplementary	O
Table	O
S2	O
and	O
S3	O
and	O
Fig	O
.	O
8B	O
).	O

Supporting	O
the	O
role	O
of	O
NIK	B-GP
in	O
CSCs	O
regulation	O
,	O
we	O
found	O
that	O
most	O
of	O
the	O
top	O
regulated	O
genes	O
were	O
involved	O
in	O
stem	O
cell	O
or	O
EMT	O
processes	O
(	O
Fig	O
.	O
8C	O
,	O
D	O
).	O

In	O
order	O
to	O
validate	O
the	O
microarray	O
data	O
,	O
seven	O
genes	O
were	O
analyzed	O
by	O
real	O
time	O
RT	O
-	O
PCR	O
.	O

We	O
based	O
this	O
selection	O
on	O
the	O
fold	O
change	O
found	O
or	O
on	O
their	O
role	O
in	O
stem	O
cell	O
biology	O
.	O

All	O
analyzed	O
genes	O
correlated	O
well	O
with	O
the	O
results	O
obtained	O
from	O
microarrays	O
(	O
Fig	O
.	O
8E	O
).	O

As	O
expected	O
,	O
we	O
observed	O
that	O
upregulated	O
genes	O
(	O
EGR1	B-GP
.	O

TCN1	B-GP
.	O

DUSP6	B-GP
,	O
GDF15	B-GP
)	O
in	O
the	O
samples	O
with	O
high	O
NIK	B-GP
expression	O
were	O
also	O
downregulated	O
in	O
MCF7	O
depleted	O
-	O
NIK	B-GP
cells	O
(	O
Fig	O
.	O
8E	O
).	O

Ingenuity	O
Pathway	O
Analysis	O
(	O
IPA	O
)	O
of	O
MCF7	O
cells	O
overexpressing	O
NIK	B-GP
showed	O
concordant	O
enriched	O
signaling	O
networks	O
,	O
including	O
cellular	O
growth	O
and	O
proliferation	O
,	O
cell	O
death	O
and	O
survival	O
,	O
cellular	O
movement	O
and	O
hematological	O
system	O
development	O
.	O

These	O
results	O
indicate	O
that	O
NIK	B-GP
disruption	O
could	O
impair	O
the	O
proliferation	O
,	O
survival	O
,	O
and	O
migration	O
of	O
cancer	B-DS
stem	O
cells	O
.	O

Our	O
microarray	O
results	O
suggest	O
that	O
NIK	B-GP
could	O
activate	O
ERK1	B-GP
/	O
2	O
pathway	O
to	O
regulate	O
several	O
molecules	O
involved	O
in	O
stem	O
cell	O
modulation	O
such	O
as	O
EGR1	B-GP
,	O
NCF1	B-GP
,	O
COL5A2	B-GP
and	O
GDF15	B-GP
)	O
(	O
Fig	O
.	O
8F	O
).	O

In	O
addition	O
,	O
our	O
results	O
showed	O
that	O
NIK	B-GP
deficiency	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
stem	O
cell	O
-	O
associated	O
genes	O
such	O
as	O
MAP2K6	B-GP
,	O
CSPG4	B-GP
,	O
and	O
TAL1	B-GP
,	O
probably	O
by	O
the	O
MAPK	B-GP
and	O
ERK1	B-GP
/	O
2	O
pathway	O
(	O
Fig	O
.	O
8G	O
).	O

Data	O
analysis	O
of	O
deregulated	O
genes	O
in	O
MCF7	O
cells	O
with	O
high	O
NIK	B-GP
expression	O
revealed	O
that	O
ERK	B-GP
could	O
be	O
one	O
of	O
the	O
key	O
pathways	O
that	O
contribute	O
to	O
regulate	O
the	O
stem	O
cell	O
phenotype	O
.	O

NIK	B-GP
regulates	O
stemness	O
through	O
ERK	B-GP
activation	O

The	O
ERK	B-GP
pathway	O
is	O
involved	O
in	O
the	O
activation	O
of	O
many	O
transcription	B-GP
factors	I-GP
,	O
which	O
promote	O
cancer	B-DS
cell	O
growth	O
and	O
tumorigenesis	O
.	O

Interestingly	O
,	O
our	O
results	O
showed	O
that	O
NIK	B-GP
could	O
be	O
regulating	O
the	O
ERK	B-GP
pathway	O
to	O
modulated	O
target	O
genes	O
involved	O
in	O
stemness	O
or	O
epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
),	O
a	O
process	O
that	O
gives	O
rise	O
to	O
cancer	B-DS
stem	O
-	O
like	O
cells	O
.	O

To	O
determine	O
the	O
role	O
of	O
NIK	B-GP
in	O
ERK	B-GP
activation	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
status	O
of	O
ERK	B-GP
in	O
NIK	B-GP
-	O
deficient	O
and	O
NIK	B-GP
-	O
over	O
-	O
expressing	O
cells	O
.	O

Forced	O
expression	O
of	O
NIK	B-GP
promoted	O
ERK	B-GP
phosphorylation	O
,	O
while	O
NIK	B-GP
depletion	O
reduced	O
the	O
expression	O
of	O
phospho	O
-	O
ERK	B-GP
(	O
Fig	O
.	O
9A	O
).	O

These	O
results	O
suggest	O
that	O
NIK	B-GP
modulates	O
ERK	B-GP
phosphorylation	O
in	O
BCSC	O
.	O

To	O
further	O
support	O
the	O
role	O
or	O
ERK	B-GP
in	O
the	O
NIK	B-GP
-	O
mediated	O
stem	O
phenotype	O
,	O
we	O
used	O
a	O
chemical	O
inhibitor	O
of	O
this	O
kinase	B-GP
.	O

As	O
expected	O
,	O
ERK	B-GP
inhibition	O
with	O
FR180204	O
resulted	O
in	O
a	O
reduced	O
expression	O
of	O
the	O
upregulated	O
genes	O
found	O
in	O
the	O
microarray	O
data	O
(	O
Early	O
Growth	O
Response	O
1	O
,	O
EGR1	B-GP
;	O
Growth	B-GP
Differentiation	I-GP
Factor	I-GP
15	I-GP
,	O
GDF15	B-GP
;	O
Transcobalamin	B-GP
1	I-GP
,	O
TCN1	B-GP
and	O
Dual	B-GP
specificity	I-GP
phosphatase	I-GP
6	I-GP
,	O
DUSP6	B-GP
)	O
(	O
Fig	O
.	O
9B	O
).	O

To	O
verify	O
the	O
role	O
of	O
ERK	B-GP
in	O
the	O
regulation	O
of	O
these	O
target	O
genes	O
,	O
we	O
used	O
specific	O
shRNAs	O
directed	O
against	O
ERK1	B-GP
and	O
ERK2	B-GP
(	O
Supplementary	O
Fig	O
.	O

S5A	O
).	O

Our	O
results	O
showed	O
that	O
ERK	B-GP
inhibition	O
also	O
reduced	O
the	O
expression	O
of	O
EGR1	B-GP
and	O
GDF15	B-GP
,	O
but	O
failed	O
to	O
reduce	O
DUSP6	B-GP
expression	O
(	O
Supplementary	O
Fig	O
.	O

S5B	O
).	O

Interestingly	O
,	O
NIK	B-GP
-	O
overexpressing	O
MCF7	O
cells	O
exposed	O
to	O
FR180204	O
fail	O
to	O
up	O
-	O
regulate	O
target	O
genes	O
(	O
Fig	O
.	O
9C	O
).	O

Since	O
NIK	B-GP
leads	O
to	O
an	O
increase	O
in	O
ERK	B-GP
activation	O
,	O
we	O
analyzed	O
whether	O
the	O
inhibition	O
of	O
ERK	B-GP
signaling	O
decreases	O
the	O
ability	O
of	O
NIK	B-GP
to	O
enhance	O
CSC	O
fraction	O
.	O

Administration	O
of	O
FR180204	O
to	O
NIK	B-GP
-	O
overexpressing	O
cells	O
dramatically	O
reduced	O
the	O
CSC	O
fraction	O
to	O
numbers	O
close	O
to	O
those	O
found	O
in	O
MCF7	O
control	O
cells	O
(	O
Fig	O
.	O
9D	O
).	O

Discussion	O

It	O
has	O
been	O
proposed	O
that	O
a	O
subpopulation	O
of	O
cancer	B-DS
stem	O
cells	O
are	O
able	O
to	O
initiate	O
and	O
sustain	O
the	O
growth	O
of	O
a	O
tumor1	O
,	O
enabling	O
the	O
propagation	O
and	O
formation	O
of	O
metastatic	O
foci	O
at	O
distant	O
sites263132	O
.	O

According	O
to	O
this	O
hypothesis	O
,	O
only	O
CSCs	O
can	O
self	O
-	O
renew	O
indefinitely	O
and	O
differentiate	O
into	O
all	O
tumor	B-DS
cell	O
types33	O
.	O

The	O
identification	O
of	O
new	O
CSC	O
targets	O
could	O
be	O
very	O
useful	O
,	O
particularly	O
for	O
neoplasms	B-DS
with	O
high	O
mortality	O
and	O
early	O
relapse	O
rates	O
.	O

Gene	O
expression	O
profiles	O
have	O
defined	O
the	O
following	O
five	O
breast	B-DS
cancer	I-DS
subtypes	O
:	O
luminal	O
-	O
like	O
,	O
basal	O
-	O
like	O
,	O
HER2	B-GP
enriched	O
,	O
claudin	B-GP
-	O
low	O
,	O
and	O
normal	O
breast	O
-	O
like3435	O
.	O

In	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
,	O
NF	B-GP
-	I-GP
κB	I-GP
activity	O
is	O
differentially	O
represented	O
in	O
luminal	O
and	O
basal	O
breast	B-DS
tumor	I-DS
subtype	O
.	O

Basal	O
breast	B-DS
cancer	I-DS
cell	O
lines	O
possess	O
increased	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
state	O
and	O
high	O
NIK	B-GP
expression2021	O
.	O

NIK	B-GP
expression	O
in	O
breast	B-DS
cancer	I-DS
tissues	O
has	O
not	O
been	O
analyzed	O
;	O
here	O
we	O
show	O
that	O
HER2	B-GP
breast	B-DS
tumors	I-DS
expressed	O
higher	O
levels	O
of	O
NIK	B-GP
than	O
Triple	O
Negative	O
tumors	B-DS
.	O

Supporting	O
this	O
result	O
,	O
it	O
has	O
been	O
showed	O
that	O
active	O
NF	B-GP
-	I-GP
κB	I-GP
is	O
detected	O
mainly	O
in	O
the	O
HER2	B-GP
+/	O
ER	O
-	O
negative	O
subtype	O
in	O
breast	B-DS
tumor	I-DS
specimens36	O
.	O

In	O
addition	O
,	O
it	O
is	O
well	O
known	O
that	O
HER2	B-GP
overexpression	O
induces	O
NF	B-GP
-	I-GP
κB	I-GP
activation373839	O
.	O

Furthermore	O
,	O
it	O
was	O
reported	O
that	O
HER2	B-GP
is	O
an	O
important	O
regulator	O
of	O
BCSCs	O
in	O
HER2	B-GP
-	O
positive	O
tumors40	O
.	O

HER2	B-GP
appears	O
to	O
regulate	O
self	O
-	O
renewal	O
in	O
breast	B-DS
tumors	I-DS
lacking	O
HER2	B-GP
amplification	O
through	O
the	O
receptor	B-GP
activator	I-GP
of	I-GP
NF	I-GP
-	I-GP
κB	I-GP
(	O
RANK	B-GP
)-	O
ligand41	O
.	O

Baldwin	O
AS	O
in	O
2010	O
using	O
Her2	B-GP
+/	O
ER	O
-	O
breast	B-DS
cancer	I-DS
cells	O
,	O
showed	O
that	O
HER2	B-GP
activates	O
NF	B-GP
-	I-GP
kappa	I-GP
B	I-GP
via	O
IKKα	B-GP
and	O
hypothesized	O
that	O
NIK	B-GP
might	O
be	O
activating	O
IKKα	B-GP
since	O
NIK	B-GP
has	O
been	O
associated	O
to	O
the	O
ErbB2	B-GP
family	O
member	O
EGFR37	B-GP
.	O

Nevertheless	O
,	O
the	O
mechanism	O
of	O
how	O
HER2	B-GP
regulates	O
NIK	B-GP
is	O
not	O
currently	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
established	O
a	O
strong	O
association	O
between	O
NIK	B-GP
and	O
the	O
CSC	O
phenotype	O
.	O

We	O
observed	O
that	O
the	O
majority	O
of	O
the	O
stem	O
cell	O
markers	O
analyzed	O
were	O
co	O
-	O
regulated	O
by	O
NIK	B-GP
.	O

Our	O
data	O
showed	O
that	O
NIK	B-GP
expression	O
was	O
higher	O
in	O
BCSCs	O
derived	O
from	O
both	O
luminal	O
and	O
triple	B-DS
negative	I-DS
breast	I-DS
cancer	I-DS
cell	O
lines	O
.	O

NIK	B-GP
depletion	O
reduced	O
the	O
BCSC	O
subpopulation	O
and	O
dramatically	O
impaired	O
malignant	O
characteristics	O
such	O
as	O
tumorigenicity	O
and	O
clonogenicity	O
in	O
both	O
cell	O
lines	O
.	O

Interestingly	O
,	O
even	O
when	O
MCF7	O
cells	O
expressed	O
low	O
levels	O
of	O
NIK	B-GP
,	O
inhibition	O
of	O
NIK	B-GP
was	O
sufficient	O
to	O
reduce	O
the	O
BCSC	O
population	O
and	O
to	O
impact	O
clonogenic	O
abilities	O
.	O

These	O
results	O
support	O
the	O
strong	O
contribution	O
of	O
this	O
kinase	B-GP
to	O
the	O
stem	O
cell	O
-	O
like	O
phenotype	O
in	O
breast	B-DS
cancer	I-DS
.	O

Our	O
results	O
showed	O
that	O
NIK	B-GP
expression	O
regulates	O
CSC	O
markers	O
expression	O
,	O
interestingly	O
,	O
ALDH1A1	B-GP
,	O
ALDH1A3	B-GP
have	O
promoters	O
with	O
putative	O
NF	B-GP
-	I-GP
κB	I-GP
-	O
responsive	O
elements	O
.	O

Analysis	O
of	O
breast	B-DS
cancer	I-DS
tissues	O
revealed	O
that	O
ALDH	B-GP
-	O
expressing	O
cells	O
also	O
express	O
NIK	B-GP
protein	O
in	O
the	O
majority	O
of	O
the	O
tumor	B-DS
analyzed	O
.	O

These	O
results	O
suggest	O
that	O
a	O
NIK	B-GP
-	O
ALDH	B-GP
-	O
dependent	O
regulation	O
of	O
the	O
BCSC	O
population	O
likely	O
operates	O
in	O
vivo	O
.	O

Our	O
data	O
showed	O
that	O
NIK	B-GP
expression	O
negatively	O
regulates	O
CD24	B-GP
.	O

Vesuna	O
et	O
al	O
.,	O
found	O
that	O
Twist	O
,	O
an	O
EMT	O
inductor	O
regulated	O
by	O
NF	B-GP
-	I-GP
κB	I-GP
,	O
is	O
able	O
to	O
repress	O
the	O
transcription	O
of	O
CD2442	O
.	O

Interestingly	O
,	O
our	O
group	O
has	O
shown	O
that	O
modulation	O
of	O
NIK	B-GP
expression	O
affects	O
Twist	O
levels	O
(	O
data	O
no	O
shown	O
,	O
manuscript	O
in	O
preparation	O
).	O

CD24	B-GP
has	O
been	O
reported	O
to	O
suppress	O
NF	B-GP
-	I-GP
κB	I-GP
signaling	O
and	O
to	O
potentiate	O
DNA	O
damage	O
-	O
induced	O
apoptosis43	O
.	O

Thus	O
,	O
CD24	B-GP
and	O
NF	B-GP
-	I-GP
κB	I-GP
could	O
be	O
participating	O
in	O
a	O
negative	O
feedback	O
that	O
ultimately	O
determines	O
the	O
final	O
CSC	O
fraction	O
of	O
a	O
tumor	B-DS
.	O

NIK	B-GP
can	O
activate	O
both	O
canonical	O
and	O
non	O
-	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathways44	O
.	O

NIK	B-GP
preferentially	O
phosphorylates	O
IKKα	B-GP
,	O
although	O
it	O
can	O
also	O
phosphorylate	O
IKKβ	B-GP
in	O
an	O
IKKα	B-GP
-	O
dependent	O
manner45	O
.	O

In	O
this	O
article	O
,	O
we	O
demonstrated	O
that	O
NIK	B-GP
overexpression	O
induces	O
NF	B-GP
-	I-GP
κB	I-GP
activation	O
and	O
enhances	O
the	O
expression	O
of	O
p52	B-GP
,	O
p65	B-GP
,	O
and	O
RelB	B-GP
,	O
suggesting	O
that	O
components	O
of	O
non	O
-	O
canonical	O
and	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathways	O
are	O
involved	O
in	O
NIK	B-GP
-	O
mediated	O
stem	O
cell	O
phenotype	O
modulation	O
.	O

Regulation	O
of	O
NANOG	B-GP
and	O
SOX2	B-GP
by	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
has	O
been	O
described	O
previously46	O
,	O
however	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
regulation	O
of	O
ALDH	B-GP
genes	O
by	O
this	O
pathway	O
.	O

The	O
role	O
of	O
NF	B-GP
-	I-GP
κB	I-GP
pathways	O
in	O
BCSCs	O
has	O
not	O
been	O
completely	O
elucidated	O
;	O
however	O
,	O
it	O
is	O
clear	O
that	O
NF	B-GP
-	I-GP
κB	I-GP
is	O
involved	O
in	O
BCSCs	O
regulation	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
BCSCs	O
express	O
higher	O
levels	O
of	O
NIK	B-GP
,	O
suggesting	O
that	O
NF	B-GP
-	I-GP
κB	I-GP
performs	O
an	O
important	O
role	O
in	O
BCSCs	O
.	O

Interestingly	O
;	O
NF	B-GP
-	I-GP
κB	I-GP
inhibitors	O
preferentially	O
reduced	O
breast	B-DS
cancer	I-DS
stem	O
-	O
like	O
cell	O
proliferation	O
,	O
with	O
fewer	O
effects	O
on	O
bulk	O
population47	O
.	O

Thus	O
,	O
NF	B-GP
-	I-GP
κB	I-GP
disruption	O
could	O
be	O
used	O
as	O
a	O
therapeutic	O
approach	O
to	O
target	O
BCSCs	O
.	O

Still	O
,	O
more	O
work	O
needs	O
to	O
be	O
done	O
to	O
clarify	O
the	O
role	O
of	O
non	O
-	O
canonical	O
and	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathways	O
in	O
BCSCs	O
.	O

However	O
,	O
there	O
is	O
enough	O
evidence	O
showing	O
that	O
both	O
pathways	O
regulate	O
BCSCs	O
.	O

It	O
is	O
well	O
known	O
that	O
IKKβ	B-GP
-	O
mediated	O
suppression	O
of	O
the	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
in	O
the	O
mammary	O
gland	O
significantly	O
reduces	O
CSC	O
populations	O
,	O
impairs	O
mammosphere	O
-	O
forming	O
abilities	O
,	O
and	O
reduces	O
tumorigenicity4648	O
.	O

Similarly	O
,	O
IKKα	B-GP
also	O
contributes	O
to	O
BCSC	O
self	O
-	O
renewal	O
,	O
because	O
IKKαAA	O
/	O
AA	O
knock	O
-	O
in	O
mice	B-OG
exhibit	O
delays	O
in	O
the	O
development	O
of	O
breast	B-DS
tumors	I-DS
from	O
cells	O
that	O
cannot	O
develop	O
secondary	O
mammospheres49	O
.	O

In	O
support	O
of	O
our	O
results	O
,	O
a	O
recent	O
study	O
showed	O
that	O
NIK	B-GP
/	O
IKKα	B-GP
promotes	O
breast	O
basal	O
cell	O
expansion	O
and	O
mammosphere	O
-	O
forming	O
ability	O
in	O
a	O
mouse	B-OG
model	O
.	O

The	O
NIK	B-GP
-	O
IKKα	B-GP
cascade	O
acts	O
as	O
an	O
important	O
regulator	O
of	O
the	O
cyclin	B-GP
-	I-GP
dependent	I-GP
kinase	I-GP
inhibitor	O
that	O
enters	O
the	O
nucleus	O
and	O
phosphorylates	O
p27	B-GP
to	O
stimulate	O
its	O
nuclear	O
export24	O
.	O

In	O
addition	O
,	O
it	O
was	O
recently	O
shown	O
that	O
the	O
induction	O
of	O
the	O
non	O
-	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
through	O
NIK	B-GP
activation	O
regulates	O
Jagged1	B-GP
(	O
JAG1	B-GP
)	O
expression	O
and	O
expands	O
the	O
stem	O
cell	O
population	O
in	O
the	O
basal	O
-	O
like	O
breast	B-DS
cancer	I-DS
subtype21	O
.	O

The	O
mechanism	O
by	O
which	O
NIK	B-GP
mediates	O
regulation	O
of	O
the	O
CSC	O
phenotype	O
is	O
poorly	O
understood	O
.	O

Our	O
results	O
showed	O
that	O
NIK	B-GP
regulates	O
the	O
expression	O
of	O
stem	O
cells	O
-	O
related	O
genes	O
through	O
activation	O
of	O
both	O
NF	B-GP
-	I-GP
KB	I-GP
and	O
ERK1	B-GP
/	O
2	O
pathway	O
.	O

We	O
found	O
that	O
phosphorylation	O
of	O
ERK1	B-GP
/	O
2	O
is	O
regulated	O
upstream	O
by	O
NIK	B-GP
,	O
and	O
that	O
both	O
NIK	B-GP
and	O
ERK1	B-GP
/	O
2	O
are	O
required	O
to	O
regulate	O
stemness	O
in	O
breast	B-DS
cancer	I-DS
cells	O
.	O

Supporting	O
our	O
results	O
,	O
Richmond	O
Ann	O
and	O
Dhawan	O
Punita	O
,	O
showed	O
that	O
NIK	B-GP
activates	O
ERK1	B-GP
/	O
2	O
via	O
MEK1	B-GP
/	O
2	O
in	O
melanoma	B-DS
cell	O
lines	O
,	O
which	O
have	O
high	O
NIK	B-GP
basal	O
expression	O
.	O

In	O
addition	O
,	O
Gingery	O
in	O
2008	O
demonstrated	O
that	O
in	O
osteoclasts	O
,	O
MEK1	B-GP
/	O
2	O
activates	O
AKT	B-GP
,	O
which	O
in	O
turn	O
phosphorylates	O
NIK5051	O
.	O

Among	O
the	O
molecules	O
regulated	O
by	O
ERK1	B-GP
,	O
we	O
found	O
several	O
genes	O
previously	O
described	O
to	O
be	O
highly	O
expressed	O
in	O
various	O
types	O
of	O
CSCs	O
,	O
such	O
as	O
miR	O
-	O
21	O
,	O
EGR1	B-GP
and	O
GDF15	B-GP
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
EGR1	B-GP
plays	O
a	O
critical	O
role	O
in	O
the	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
52	O
,	O
a	O
process	O
involved	O
in	O
the	O
acquisition	O
of	O
cancer	B-DS
stem	O
cells	O
properties53	O
.	O

EGR1	B-GP
controls	O
stem	O
cell	O
proliferation54	O
,	O
migration	O
and	O
tumor	B-DS
growth5556	O
.	O

EGR1	B-GP
is	O
mainly	O
regulated	O
by	O
the	O
ERK1	B-GP
/	O
2	O
and	O
NF	B-GP
-	I-GP
κB	I-GP
pathways57	O
.	O

Interestingly	O
,	O
EGR1	B-GP
participates	O
in	O
the	O
EMT	O
by	O
down	O
-	O
regulating	O
E	B-GP
-	I-GP
cadherin	I-GP
through	O
SNAIL58	B-GP
.	O

Microarray	O
expression	O
analysis	O
revealed	O
that	O
EGR1	B-GP
target	O
genes	O
such	O
as	O
GDF15	B-GP
are	O
also	O
highly	O
expressed	O
in	O
NIK	B-GP
-	O
overexpressing	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
NIK	B-GP
also	O
mediates	O
stem	O
cell	O
phenotype	O
through	O
the	O
induction	O
of	O
genes	O
involved	O
in	O
the	O
EMT	O
process	O
.	O

Because	O
NIK	B-GP
contributes	O
to	O
the	O
tumorigenic	O
potential	O
of	O
BCSCs	O
,	O
its	O
inhibition	O
could	O
be	O
an	O
effective	O
way	O
to	O
target	O
BCSC	O
and	O
to	O
reduce	O
tumor	B-DS
progression	O
.	O

Due	O
to	O
that	O
NIK	B-GP
is	O
not	O
an	O
essential	O
kinase	B-GP
for	O
canonical	O
NF	B-GP
-	I-GP
κB	I-GP
pathway	O
activation	O
under	O
normal	O
physiological	O
conditions	O
,	O
NIK	B-GP
inhibitors	O
could	O
be	O
safer	O
than	O
more	O
general	O
strategies	O
;	O
however	O
,	O
further	O
studies	O
are	O
required	O
.	O

Conclusions	O

In	O
the	O
present	O
report	O
,	O
we	O
present	O
strong	O
evidence	O
that	O
NIK	B-GP
is	O
a	O
critical	O
kinase	B-GP
for	O
the	O
BCSC	O
phenotype	O
because	O
it	O
modulates	O
stem	O
cell	O
markers	O
,	O
as	O
well	O
as	O
the	O
clonogenic	O
potential	O
and	O
tumorigenicity	O
of	O
these	O
cells	O
.	O

This	O
kinase	B-GP
is	O
an	O
attractive	O
stem	O
cell	O
marker	O
in	O
both	O
luminal	O
and	O
basal	O
tumor	B-DS
types	O
and	O
could	O
possibly	O
be	O
an	O
important	O
therapeutic	O
target	O
.	O

Methods	O

Cell	O
culture	O
and	O
reagents	O

MCF7	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
SKBR3	O
cell	O
lines	O
were	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
,	O
Manassas	O
,	O
VA	O
,	O
USA	O
;	O
www	O
.	O
atcc	O
.	O
org	O
).	O

MCF7	O
cells	O
were	O
cultured	O
in	O
RPMI	O
1640	O
supplemented	O
with	O
5	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
),	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
were	O
maintained	O
in	O
DMEM	O
supplemented	O
with	O
5	O
%	O
FBS	O
and	O
SKBR3	O
were	O
cultured	O
in	O
McCoy	O
’	O
s	O
5A	O
supplemented	O
with	O
10	O
%	O
FBS	O
.	O

All	O
cell	O
lines	O
were	O
cultured	O
in	O
a	O
humidified	O
atmosphere	O
at	O
37	O
°	O
C	O
with	O
5	O
%	O
CO2	O
.	O

Flow	O
cytometry	O
analysis	O

Cells	O
were	O
detached	O
with	O
Accutase	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
and	O
washed	O
with	O
Phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
1	O
%	O
and	O
resuspended	O
in	O
the	O
stain	O
buffer	O
(	O
PBS	O
with	O
FBS	O
1	O
%).	O

A	O
total	O
of	O
1	O
×	O
106	O
cells	O
were	O
incubated	O
with	O
the	O
FITC	O
-	O
CD44	B-GP
(	O
555478	O
,	O
BD	O
Biosciences	O
)	O
and	O
PE	O
-	O
CD24	B-GP
(	O
555428	O
,	O
BD	O
Biosciences	O
)	O
for	O
30	O
min	O
on	O
ice	O
.	O

MDA	O
-	O
MB	O
-	O
231	O
cells	O
were	O
also	O
labeled	O
with	O
APC	O
-	O
ESA	B-GP
(	O
347200	O
,	O
BD	O
Biosciences	O
)	O
for	O
30	O
min	O
.	O

FITC	O
-	O
IgG1	B-GP
(	O
130	O
-	O
092	O
-	O
213	O
,	O
Miltenyi	O
Biotec	O
),	O
PE	O
-	O
IgG1	B-GP
(	O
130	O
-	O
092	O
-	O
212	O
,	O
Miltenyi	O
Biotec	O
)	O
and	O
APC	O
-	O
IgG1	B-GP
(	O
130	O
-	O
092	O
-	O
214	O
,	O
Miltenyi	O
Biotec	O
)	O
antibody	O
isotype	O
were	O
used	O
as	O
controls	O
.	O

For	O
cell	O
sorting	O
,	O
1	O
×	O
108	O
MCF7	O
cells	O
were	O
sorted	O
into	O
CD44	B-GP
+/	O
CD24	B-GP
−/	O
low	O
and	O
CD44	B-GP
+/	O
CD24	B-GP
+	O
subsets	O
.	O

MDA	O
-	O
MB	O
-	O
231	O
cells	O
were	O
sorted	O
into	O
ESA	B-GP
+	O
and	O
ESA	B-GP
−	O
subsets	O
.	O

Cells	O
were	O
sorted	O
on	O
a	O
FACSAria	O
(	O
fluorescence	O
-	O
activated	O
cell	O
sorter	O
,	O
Becton	O
Dickinson	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
,	O
USA	O
)	O
and	O
then	O
were	O
harvested	O
and	O
grown	O
under	O
standard	O
culture	O
conditions	O
for	O
24	O
h	O
prior	O
to	O
any	O
further	O
procedures	O
.	O

ALDH	B-GP
+	O
population	O
was	O
separated	O
by	O
FACS	O
.	O

ALDH1	B-GP
activity	O
was	O
determined	O
using	O
the	O
Aldeflour	O
assay	O
(	O
Stem	O
Cell	O
Technologies	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Briefly	O
,	O
1	O
×	O
106	O
cells	O
were	O
suspended	O
in	O
Aldeflour	O
assay	O
and	O
incubated	O
with	O
5	O
ul	O
of	O
activated	O
Aldeflour	O
reagent	O
during	O
30	O
minutes	O
.	O

Control	O
cells	O
were	O
incubated	O
with	O
Aldeflour	O
reagent	O
along	O
with	O
5	O
ul	O
of	O
DEAB	O
solution	O
.	O

The	O
brightly	O
fluorescent	O
ALDH1	B-GP
-	O
expressing	O
cells	O
were	O
detected	O
in	O
the	O
FITC	O
channel	O
on	O
a	O
FACSAria	O
cell	O
sorter	O
.	O

Cells	O
were	O
harvested	O
and	O
grown	O
under	O
standard	O
culture	O
condition	O
for	O
24	O
h	O
prior	O
to	O
RNA	O
isolation	O
.	O

RT	O
-	O
PCR	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O

Total	O
RNA	O
was	O
isolated	O
with	O
TRIzol	O
reagent	O
(	O
Life	O
Technologies	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Then	O
,	O
2	O
μg	O
of	O
RNA	O
was	O
reverse	O
transcribed	O
with	O
a	O
Maxima	O
First	O
strand	O
cDNA	O
synthesis	O
kit	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
).	O

RT	O
-	O
qPCR	O
was	O
performed	O
by	O
the	O
7900HT	O
(	O
Applied	O
Biosystems	O
)	O
or	O
the	O
QuantStudio	O
7	O
.	O

PCR	O
was	O
performed	O
with	O
the	O
SYBR	O
-	O
select	O
Master	O
Kit	O
(	O
Applied	O
Biosystems	O
).	O

Primers	O
listed	O
in	O
Supplementary	O
Table	O
S4	O
were	O
used	O
for	O
qRT	O
-	O
PCR	O
.	O

Protein	O
preparation	O
and	O
Western	O
Blotting	O

Total	O
proteins	O
were	O
extracted	O
with	O
RIPA	O
buffer	O
(	O
Upstate	O
Biotechnology	O
,	O
Inc	O
.,	O
Lake	O
Placid	O
,	O
New	O
York	O
,	O
USA	O
)	O
supplied	O
with	O
protease	B-GP
and	O
phosphatase	B-GP
inhibitors	O
.	O

Subcellular	O
fraction	O
was	O
carried	O
out	O
with	O
the	O
Subcellular	O
Protein	O
Fractionation	O
Kit	O
(	O
Thermo	O
Scientific	O
,	O
MA	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Proteins	O
were	O
resolved	O
in	O
10	O
%	O
SDS	O
-	O
PAGE	O
and	O
transferred	O
onto	O
polyvinylidene	O
difluoride	O
(	O
PVDF	O
)	O
membranes	O
(	O
Millipore	O
,	O
Bedford	O
,	O
MA	O
,	O
USA	O
).	O

Membranes	O
were	O
blocked	O
with	O
5	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
in	O
Tris	O
-	O
buffered	O
saline	O
with	O
0	O
.	O
1	O
%	O
Tween	O
(	O
TBST	O
)	O
for	O
2	O
h	O
,	O
then	O
were	O
incubated	O
overnight	O
with	O
the	O
corresponding	O
antibodies	O
at	O
4	O
°	O
C	O
,	O
followed	O
by	O
incubation	O
with	O
horseradish	B-OG
peroxidase	B-GP
-	O
conjugated	O
goat	B-OG
anti	O
-	O
mouse	B-OG
IgG	B-GP
(	O
W402B	O
,	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
or	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
IgG	B-GP
(	O
W401B	O
,	O
Promega	O
),	O
or	O
rabbit	B-OG
anti	O
-	O
Goat	B-OG
IgG	B-GP
(	O
Zymax	O
,	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
as	O
appropriate	O
,	O
for	O
1	O
h	O
at	O
RT	O
in	O
TBST	O
.	O

Antibody	O
binding	O
was	O
detected	O
with	O
the	O
Immobilon	O
Western	O
kit	O
(	O
Millipore	O
),	O
and	O
images	O
were	O
visualized	O
with	O
the	O
VersaDoc	O
Imaging	O
System	O
(	O
BioRad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
).	O

The	O
antibodies	O
used	O
were	O
,	O
anti	O
-	O
p65	B-GP
(	O
1	O
:	O
1000	O
,	O
sc372	O
,	O
Santa	O
Cruz	O
Biotechnology	O
CA	O
,	O
USA	O
),	O
anti	O
-	O
RelB	B-GP
(	O
1	O
:	O
1000	O
,	O
sc28689	O
,	O
Santa	O
Cruz	O
Biotechnology	O
),	O
anti	O
-	O
p50	B-GP
(	O
1	O
:	O
1000	O
,	O
sc1190	O
,	O
Santa	O
Cruz	O
Biotechnology	O
),	O
anti	O
-	O
p52	B-GP
(	O
1	O
:	O
1000	O
,	O
05	O
–	O
361	O
,	O
Millipore	O
),	O
anti	O
-	O
p	O
-	O
ERK1	B-GP
/	O
2	O
(	O
1	O
:	O
10000	O
,	O
Cell	O
Signaling	O
),	O
anti	O
-	O
αtubulin	B-GP
(	O
1	O
:	O
2000	O
,	O
sc53646	O
,	O
Santa	O
Cruz	O
Biotechnology	O
),	O
anti	O
-	O
GAPDH	B-GP
(	O
1	O
:	O
5000	O
,	O
sc25778	O
,	O
Santa	O
Cruz	O
)	O
and	O
anti	O
-	O
Laminin	B-GP
A	O
/	O
C	O
(	O
1	O
:	O
1000	O
,	O
4777	O
,	O
Cell	O
Signaling	O
).	O

shRNA	O
experiments	O

To	O
decrease	O
NIK	B-GP
expression	O
,	O
two	O
shRNAs	O
(	O
1	O
:	O
CCGAGAGTCTTGATCAGAT	O
,	O
2	O
:	O
GGTCAACATCTTCATGGA	O
,	O
and	O
3	O
:	O
GAGGAATACCTAGTGCAT	O
,)	O
were	O
designed	O
with	O
the	O
RNAi	O
Target	O
Sequence	O
Selector	O
(	O
Clontech	O
).	O

To	O
decrease	O
ERK1	B-GP
and	O
ERK2	B-GP
expression	O
,	O
we	O
designed	O
two	O
shRNAs	O
for	O
each	O
gene	O
(	O
1	O
:	O
GGATCAGCTCAACCACATT	O
,	O
2	O
:	O
CCTCCAACCTGCTCATCAA	O
,	O
3	O
:	O
CACCAACCATCGAGCAAAT	O
,	O
4	O
:	O
CAGCCAGGATACAGATCTT	O
).	O

All	O
shRNAs	O
were	O
cloned	O
into	O
the	O
pSIREN	O
RQ	O
-	O
vector	O
(	O
Clontech	O
).	O

shRNA	O
against	O
luciferase	B-GP
was	O
used	O
as	O
a	O
control	O
.	O

MCF7	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
and	O
SKBR3	O
cells	O
were	O
transfected	O
and	O
then	O
selected	O
with	O
0	O
.	O
5	O
-	O
μg	O
/	O
ml	O
puromycin	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
),	O
7	O
.	O
5	O
μg	O
/	O
ml	O
puromycin	O
or	O
0	O
.	O
6	O
μg	O
/	O
ml	O
for	O
3	O
weeks	O
respectively	O
.	O

ERK	B-GP
pathway	O
inhibition	O

A	O
selective	O
ERK	B-GP
inhibitor	O
FR180204	O
(	O
Tocris	O
,	O
Biosciences	O
)	O
was	O
employed	O
in	O
MCF7	O
cells	O
to	O
explore	O
the	O
role	O
of	O
ER	O
in	O
stemness	O
.	O

Briefly	O
MCF7	O
control	O
or	O
overexpressing	O
NIK	B-GP
cells	O
were	O
treated	O
with	O
30	O
μM	O
for	O
24	O
h	O
.	O

As	O
a	O
control	O
,	O
cells	O
were	O
treated	O
with	O
an	O
equivalent	O
volume	O
of	O
DMSO	O
.	O

ERK	B-GP
inhibition	O
was	O
verified	O
in	O
a	O
western	O
blot	O
assay	O
.	O

NIK	B-GP
overexpression	O
experiments	O

To	O
overexpress	O
NIK	B-GP
,	O
we	O
generated	O
an	O
expression	O
vector	O
by	O
recombining	O
a	O
pENTR221	O
vector	O
(	O
Life	O
Technologies	O
)	O
containing	O
the	O
ORF	O
of	O
NIK	B-GP
with	O
the	O
pTREX	O
-	O
DEST30	O
vector	O
(	O
Life	O
Technologies	O
).	O

MCF7	O
and	O
SKBR3	O
cells	O
were	O
transfected	O
with	O
4	O
μg	O
of	O
(	O
pT	O
-	O
Rex	O
-	O
NIK	B-GP
),	O
in	O
the	O
presence	O
of	O
LTX	O
-	O
Lipofectamine	O
for	O
24	O
h	O
.	O

Stable	O
MCF7	O
and	O
SKBR3	O
clones	O
were	O
selected	O
with	O
300	O
μg	O
/	O
ml	O
or	O
700	O
μg	O
/	O
ml	O
of	O
G418	O
(	O
GIBCO	O
)	O
respectively	O
for	O
3	O
weeks	O
.	O

As	O
a	O
control	O
,	O
MCF7	O
and	O
SKBR3	O
cells	O
were	O
transfected	O
with	O
4	O
-	O
μg	O
pTREX	O
-	O
Lacz	B-GP
.	O

NF	B-GP
-	I-GP
κB	I-GP
reporter	O
assays	O

NF	B-GP
-	I-GP
κB	I-GP
reporter	O
assays	O
were	O
performed	O
by	O
generating	O
a	O
stable	O
MCF7	O
cell	O
line	O
bearing	O
an	O
NF	B-GP
-	I-GP
κB	I-GP
reporter	O
vector	O
.	O

These	O
cells	O
were	O
co	O
-	O
transfected	O
with	O
4	O
μg	O
of	O
pT	O
-	O
Rex	O
-	O
NIK	B-GP
,	O
pT	O
-	O
Rex	O
-	O
Lac	O
,	O
shNIK1	O
,	O
shNIK2	O
and	O
1	O
μg	O
of	O
pCMV	O
-	O
Sport	O
-	O
Gal	O
(	O
Life	O
Technologies	O
)	O
using	O
LTX	O
-	O
Lipofectamine	O
.	O

The	O
enzymatic	O
activities	O
of	O
both	O
the	O
firefly	B-OG
luciferase	B-GP
and	O
the	O
beta	B-GP
-	I-GP
galactosidase	I-GP
reporter	O
genes	O
were	O
determined	O
48	O
h	O
after	O
transfection	O
with	O
a	O
Dual	O
-	O
luciferase	B-GP
Reporter	O
Assay	O
kit	O
(	O
Promega	O
)	O
and	O
a	O
Luminescent	O
Beta	B-GP
-	I-GP
galactosidase	I-GP
Detection	O
Kit	O
(	O
Clontech	O
),	O
respectively	O
.	O

Immunofluorescence	O

Immunofluorescence	O
analysis	O
was	O
performed	O
with	O
the	O
following	O
primary	O
antibodies	O
:	O
p52	B-GP
(	O
1	O
:	O
500	O
,	O
sc848	O
,	O
Santa	O
Cruz	O
);	O
p65	B-GP
(	O
1	O
:	O
500	O
,	O
sc372	O
,	O
Santa	O
Cruz	O
Biotechnologies	O
);	O
RelB	B-GP
(	O
1	O
:	O
500	O
,	O
sc28689	O
,	O
Santa	O
Cruz	O
Biotechnology	O
);	O
P50	B-GP
(	O
1	O
:	O
250	O
,	O
sc1190	O
,	O
Santa	O
Cruz	O
Biotechnologies	O
),	O
NIK	B-GP
(	O
1	O
:	O
1000	O
,	O
4994	O
,	O
Cell	O
Signaling	O
),	O
phospho	O
-	O
p52	B-GP
(	O
1	O
:	O
500	O
,	O
Cell	O
Signaling	O
),	O
phosphor	O
-	O
p65	B-GP
(	O
1	O
:	O
500	O
,	O
3036	O
,	O
Cell	O
Signaling	O
).	O

Briefly	O
,	O
5	O
×	O
105	O
cells	O
were	O
washed	O
with	O
PBS	O
,	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
for	O
20	O
min	O
,	O
and	O
permeabilized	O
in	O
0	O
.	O
1	O
%	O
of	O
Triton	O
100	O
×	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
for	O
30	O
min	O
.	O

Cells	O
were	O
washed	O
and	O
blocked	O
with	O
5	O
%	O
Bovine	O
serum	O
albumin	B-GP
(	O
BSA	O
)	O
for	O
1	O
h	O
and	O
subsequently	O
incubated	O
with	O
primary	O
antibodies	O
for	O
2	O
h	O
at	O
RT	O
,	O
followed	O
by	O
incubation	O
with	O
the	O
secondary	O
Cy3	O
-	O
goat	B-OG
anti	O
-	O
mouse	B-OG
antibody	O
(	O
Millipore	O
)	O
or	O
Cy3	O
-	O
goat	B-OG
anti	O
-	O
rabbit	B-OG
antibody	O
(	O
Millipore	O
)	O
or	O
Cy3	O
-	O
rabbit	B-OG
-	O
anti	O
-	O
goat	B-OG
(	O
811615	O
,	O
Zymed	O
)	O
for	O
1	O
h	O
.	O

Cells	O
were	O
then	O
washed	O
and	O
slides	O
were	O
mounted	O
in	O
Everbrite	O
mounting	O
medium	O
with	O
6	O
-	O
Diamidine	O
-	O
2	O
′-	O
phenylindole	O
dihydrochloride	O
(	O
DAPI	O
,	O
Biotium	O
,	O
Inc	O
.,	O
Hayward	O
,	O
CA	O
,	O
USA	O
).	O

Fluorescence	O
analysis	O
was	O
performed	O
on	O
a	O
confocal	O
microscope	O
(	O
Zeiss	O
LSM	O
510	O
).	O

In	O
vivo	O
tumorigenic	O
assays	O

Several	O
cell	O
dilutions	O
of	O
MCF7	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
or	O
SKBR3	O
cells	O
were	O
suspended	O
in	O
100	O
ml	O
of	O
PBS	O
with	O
50	O
%	O
growth	O
factor	O
-	O
reduced	O
Matrigel	O
(	O
BD	O
Biosciences	O
,	O
Bedford	O
,	O
MA	O
,	O
USA	O
)	O
and	O
were	O
subcutaneously	O
injected	O
into	O
nu	O
/	O
nu	O
female	O
mice	B-OG
aged	O
4	O
–	O
6	O
weeks	O
.	O

Female	O
athymic	O
Balb	B-OG
-	I-OG
c	I-OG
nu	I-OG
/	I-OG
nu	I-OG
mice	I-OG
,	O
between	O
6	O
–	O
8	O
weeks	O
,	O
were	O
supplied	O
by	O
the	O
Autonomous	O
Metropolitan	O
University	O
,	O
Mexico	O
City	O
,	O
México	O
.	O

The	O
animals	B-OG
were	O
kept	O
in	O
a	O
pathogen	O
-	O
free	O
environmental	O
and	O
fed	O
ad	O
libitum	O
.	O

All	O
animal	O
procedures	O
reported	O
in	O
the	O
present	O
paper	O
were	O
performed	O
according	O
to	O
the	O
NIH	O
Animal	O
Use	O
and	O
Care	O
Guidelines	O
(	O
USA	O
).	O

The	O
local	O
institutional	O
committee	O
:	O
Comite	O
Interno	O
de	O
Cuidados	O
de	O
Animales	O
of	O
the	O
Instituto	O
Nacional	O
de	O
Cancerologia	O
(	O
CICUAL	O
-	O
INCan	O
)	O
approved	O
the	O
procedures	O
according	O
to	O
all	O
applicable	O
National	O
institutional	O
and	O
governmental	O
regulations	O
concerning	O
the	O
ethical	O
use	O
of	O
experimental	O
animals	B-OG
.	O

MCF7	O
transplants	O
were	O
allowed	O
to	O
grow	O
for	O
150	O
days	O
;	O
SKBR3	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
were	O
allowed	O
to	O
grow	O
for	O
60	O
days	O
.	O

After	O
this	O
interval	O
or	O
when	O
the	O
tumors	B-DS
reached	O
a	O
maximum	O
volume	O
of	O
700	O
mm3	O
,	O
animals	B-OG
were	O
sacrificed	O
by	O
cervical	O
dislocation	O
trying	O
to	O
minimize	O
suffering	O
.	O

Viral	O
cell	O
transduction	O
and	O
bioluminescence	O
imaging	O

MDA	O
-	O
MB	O
-	O
231	O
shLuc	O
or	O
shNIK	O
cells	O
expressing	O
Luciferase2	B-GP
-	O
eGFP	B-GP
were	O
generated	O
as	O
described	O
previously59	O
.	O

Stable	O
cells	O
were	O
selected	O
with	O
200	O
μg	O
/	O
ml	O
of	O
Zeocin	O
(	O
life	O
technologies	O
)	O
for	O
4	O
weeks	O
.	O

Mice	B-OG
were	O
given	O
an	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.)	O
injection	O
with	O
200	O
μl	O
of	O
D	O
-	O
luciferin	O
(	O
30	O
mg	O
/	O
mL	O
).	O

Mice	B-OG
were	O
anesthetized	O
with	O
isoflurane	O
(	O
2	O
%	O
in	O
1	O
L	O
/	O
min	O
oxygen	O
),	O
and	O
bioluminescence	O
images	O
were	O
acquired	O
10	O
–	O
15	O
min	O
after	O
D	O
-	O
luciferin	O
injection	O
using	O
the	O
IVIS	O
XR	O
system	O
(	O
Caliper	O
Life	O
Sciences	O
,	O
Hopkinton	O
MA	O
).	O

Colony	O
-	O
forming	O
assays	O

Briefly	O
,	O
1	O
,	O
000	O
or	O
4000	O
MCF7	O
single	O
cells	O
were	O
seeded	O
in	O
DMEM	O
medium	O
containing	O
0	O
.	O
3	O
%	O
low	O
-	O
melting	O
-	O
point	O
agarose	O
and	O
5	O
%	O
FBS	O
,	O
and	O
the	O
cells	O
were	O
plated	O
on	O
12	O
or	O
6	O
-	O
well	O
plates	O
coated	O
with	O
0	O
.	O
5	O
%	O
low	O
-	O
melting	O
-	O
point	O
agarose	O
.	O

After	O
40	O
days	O
in	O
culture	O
,	O
colonies	O
were	O
stained	O
with	O
0	O
.	O
1	O
%	O
crystal	O
violet	O
and	O
counted	O
using	O
ImageJ	O
software	O
.	O

For	O
clonogenic	O
assays	O
of	O
the	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
line	O
,	O
cells	O
were	O
seeded	O
in	O
96	O
well	O
plates	O
as	O
described	O
in	O
results	O
.	O

After	O
two	O
weeks	O
in	O
culture	O
,	O
cells	O
were	O
stained	O
with	O
0	O
.	O
1	O
%	O
crystal	O
violet	O
.	O

Sphere	O
formation	O
assays	O

Briefly	O
,	O
2	O
.	O
5	O
×	O
104	O
/	O
ml	O
single	O
cells	O
were	O
seeded	O
over	O
non	O
-	O
adherent	O
suspension	O
culture	O
flasks	O
.	O

Cells	O
were	O
cultured	O
in	O
Mammocult	O
(	O
StemCell	O
technologies	O
)	O
supplemented	O
with	O
0	O
.	O
48	O
μg	O
/	O
ml	O
hydrocortisone	O
and	O
4	O
μg	O
/	O
ml	O
heparin	O
.	O

After	O
7	O
days	O
,	O
the	O
spheres	O
were	O
counted	O
and	O
were	O
disaggregated	O
with	O
trypsin	B-GP
until	O
singles	O
cells	O
were	O
obtained	O
.	O

Single	O
cells	O
were	O
again	O
seeded	O
and	O
spheres	O
were	O
counted	O
after	O
seven	O
days	O
.	O

The	O
same	O
number	O
of	O
cells	O
was	O
seeded	O
for	O
each	O
cell	O
line	O
.	O

Tissue	O
microarray	O
construction	O

Tumor	B-DS
tissues	O
from	O
191	O
patients	O
were	O
embedded	O
in	O
paraffin	O
,	O
and	O
4	O
-	O
mm	O
sections	O
were	O
stained	O
with	O
H	O
&	O
E	O
to	O
select	O
morphologically	O
representative	O
areas	O
.	O

Tissues	O
selected	O
were	O
punched	O
with	O
a	O
1	O
-	O
mm	O
needle	O
and	O
transferred	O
onto	O
a	O
recipient	O
paraffin	O
block	O
using	O
a	O
Tissue	O
Microarray	O
ATA	O
100	O
Chemicon	O
(	O
Chemicon	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
).	O

Then	O
,	O
4	O
-	O
mm	O
sections	O
of	O
these	O
tissue	O
arrays	O
were	O
sectioned	O
and	O
placed	O
onto	O
positively	O
charged	O
slides	O
(	O
VWR	O
Superfrost	O
Plus	O
).	O

Immunohistochemical	O
analysis	O
of	O
breast	B-DS
cancer	I-DS
tissues	O

Tissue	O
sections	O
were	O
stained	O
with	O
Estrogen	B-GP
Receptor	I-GP
(	O
SP1	O
,	O
CONFIRM	O
),	O
Progesterone	B-GP
Receptor	I-GP
(	O
IE2	O
,	O
CONFIRM	O
),	O
and	O
HER2	B-GP
(	O
4B5	O
,	O
PATHWAY	O
).	O

Immunohistochemistry	O
was	O
performed	O
using	O
the	O
UltraView	O
Universal	O
DAB	O
Detection	O
Kit	O
(	O
Ventana	O
).	O

The	O
immunohistochemistry	O
of	O
NIK	B-GP
(	O
1	O
:	O
500	O
,	O
ab220442	O
)	O
and	O
ALDH	B-GP
(	O
1	O
:	O
500	O
,	O
611195	O
,	O
BD	O
)	O
was	O
performed	O
using	O
a	O
Ventana	O
Ultraview	O
DAB	O
detection	O
kit	O
(	O
Ventana	O
)	O
and	O
UltraView	O
Universal	O
Alkaline	B-GP
Phosphatase	I-GP
Red	O
Detection	O
Kit	O
(	O
Ventana	O
),	O
respectively	O
.	O

Diaminobenzidine	O
or	O
Fast	O
Red	O
was	O
employed	O
as	O
the	O
chromogen	O
,	O
and	O
hematoxylin	O
as	O
the	O
nuclear	O
counterstain	O
.	O

All	O
slides	O
were	O
processed	O
in	O
a	O
Ventana	O
BenchMark	O
XT	O
processor	O
(	O
Ventana	O
,	O
Tucson	O
,	O
AZ	O
,	O
USA	O
).	O

Slides	O
were	O
scanned	O
in	O
ScanScope	O
CS2	O
(	O
Aperio	O
)	O
and	O
image	O
analysis	O
was	O
conducted	O
in	O
ImageJ	O
.	O

This	O
study	O
has	O
used	O
paraffin	O
embedded	O
breast	B-DS
cancer	I-DS
tissue	O
obtained	O
from	O
the	O
Oncology	O
Hospital	O
in	O
the	O
XXI	O
Century	O
National	O
Medical	O
Center	O
.	O

All	O
used	O
tissues	O
were	O
part	O
of	O
residual	O
material	O
and	O
they	O
did	O
not	O
endanger	O
patients	O
diagnostic	O
.	O

Genome	O
-	O
Wide	O
Microarray	O
analysis	O

Total	O
RNA	O
from	O
MCF7	O
cells	O
transfected	O
with	O
shNIK	O
,	O
shLUC	O
or	O
pt	O
-	O
REX	O
-	O
DEST	O
-	O
NIK	B-GP
was	O
obtained	O
48	O
hrs	O
after	O
transfection	O
.	O

All	O
samples	O
were	O
treated	O
with	O
DNAse	B-GP
1	I-GP
(	O
Ambion	O
).	O

RNA	O
integrity	O
was	O
evaluated	O
with	O
a	O
Bioanalyzer	O
2100	O
(	O
Agilent	O
)	O
and	O
only	O
samples	O
with	O
an	O
RNA	O
Integrity	O
Number	O
(	O
RIN	O
)	O
greater	O
than	O
9	O
were	O
used	O
.	O

Three	O
independent	O
biological	O
replicates	O
were	O
used	O
and	O
hybridized	O
into	O
Affymetrix	O
Gene	O
ST	O
2	O
.	O
0	O
Arrays	O
at	O
the	O
INMEGEN	O
microarray	O
core	O
unit	O
.	O

Data	O
were	O
deposited	O
in	O
the	O
Gene	O
Expression	O
Omnibus	O
(	O
GEO	O
submission	O
GSE63382	O
)	O

Statistical	O
analysis	O

Flow	O
cytometry	O
data	O
were	O
analyzed	O
with	O
the	O
Flowjo	O
software	O
package	O
(	O
Treestar	O
,	O
Ashland	O
,	O
OR	O
,	O
USA	O
).	O

Densitometric	O
analysis	O
was	O
performed	O
using	O
ImageJ	O
software	O
.	O

Statistical	O
analysis	O
was	O
carried	O
out	O
using	O
GraphPad	O
,	O
and	O
a	O
5	O
%	O
level	O
was	O
considered	O
significant	O
.	O

Analysis	O
of	O
NIK	B-GP
and	O
ALDH	B-GP
expression	O
in	O
breast	B-DS
cancer	I-DS
patients	O
were	O
conducted	O
using	O
JMP	O
and	O
One	O
-	O
way	O
Analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
was	O
employed	O
to	O
determine	O
significant	O
differences	O
.	O

Microarray	O
data	O
analysis	O
was	O
performed	O
using	O
bioconductor	O
packages	O
.	O

Data	O
were	O
normalized	O
with	O
the	O
Robust	O
Multi	O
-	O
array	O
Average	O
method	O
(	O
RMA	O
)	O
contained	O
in	O
the	O
oligo	O
package	O
.	O

The	O
Limma	O
R	O
package	O
was	O
used	O
to	O
detect	O
differentially	O
expressed60	O
.	O

Genes	O
with	O
a	O
>	O
1	O
.	O
8	O
fold	O
change	O
and	O
a	O
crude	O
p	O
<	O
0	O
.	O
05	O
were	O
considered	O
for	O
further	O
analysis	O
.	O

Ingenuity	O
Pathway	O
Analysis	O
(	O
Qiagen	O
,	O
USA	O
)	O
software	O
was	O
used	O
to	O
identify	O
enriched	O
networks	O
.	O

Additional	O
Information	O

How	O
to	O
cite	O
this	O
article	O
:	O
Vazquez	O
-	O
Santillan	O
,	O
K	O
.	O
et	O
al	O
.	O
NF	O
-	O
kappaB	O
-	O
inducing	O
kinase	B-GP
regulates	O
stem	O
cell	O
phenotype	O
in	O
breast	B-DS
cancer	I-DS
.	O
Sci	O
.	O

Rep	O
.	O
6	O
,	O
37340	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
srep37340	O
(	O
2016	O
).	O

Publisher	O
’	O
s	O
note	O
:	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

Supplementary	O
Material	O

Supplementary	O
Information	O

(	O
A	O
)	O
Fluorescence	O
activated	O
cell	O
sorting	O
(	O
FACS	O
)	O
analysis	O
of	O
cell	O
surface	O
proteins	O
showing	O
proportions	O
of	O
Cancer	O
stem	O
cells	O
(	O
CD44	O
+/	O
CD24low	O
/−)	O
in	O
breast	O
cancer	O
cell	O
lines	O
.	O

(	O
B	O
)	O
FACS	O
analysis	O
of	O
CD44	O
and	O
ESA	O
showing	O
proportions	O
of	O
CSCs	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
triple	O
negative	O
)	O
cell	O
line	O
.	O

Three	O
biological	O
experiments	O
were	O
done	O
for	O
each	O
cell	O
line	O
.	O

(	O
C	O
)	O
BCSCs	O
(	O
CD44	O
+/	O
CD24low	O
/−)	O
and	O
non	O
-	O
BCSCs	O
(	O
CD44	O
−/	O
CD24	O
+)	O
populations	O
isolated	O
from	O
MCF7	O
were	O
tested	O
for	O
their	O
clonogenic	O
potential	O
in	O
soft	O
agar	O
assays	O
(	O
4	O
,	O
000	O
seeded	O
cells	O
).	O

BCSCs	O
showed	O
increased	O
clonogenic	O
ability	O
(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
D	O
)	O
To	O
confirm	O
the	O
clonogenic	O
potential	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
BCSCs	O
(	O
ESA	O
+),	O
limited	O
dilution	O
assays	O
were	O
performed	O
.	O

CD44	O
+/	O
ESA	O
+	O
or	O
CD44	O
−/	O
ESA	O
−	O
cells	O
colony	O
numbers	O
grown	O
at	O
low	O
cell	O
density	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
E	O
)	O
Cancer	O
stem	O
cell	O
markers	O
(	O
NANOG	O
,	O
OCT4	O
,	O
SOX2	O
,	O
ALDH1A1	O
,	O
ALDH8A1	O
,	O
and	O
ALDH1A3	O
)	O
expression	O
was	O
analyzed	O
by	O
Real	O
time	O
PCR	O
(	O
RT	O
-	O
qPCR	O
)	O
in	O
MCF7	O
BCSC	O
and	O
non	O
-	O
BCSC	O
populations	O
.	O

MCF7	O
BCSCs	O
showed	O
higher	O
expression	O
levels	O
of	O
CSC	O
markers	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
F	O
)	O
Real	O
Time	O
-	O
PCR	O
analysis	O
of	O
CSC	O
markers	O
showed	O
that	O
CD44	O
+/	O
ESA	O
+	O
cells	O
expressed	O
higher	O
levels	O
of	O
SOX2	O
,	O
OCT4	O
,	O
NANOG	O
and	O
ALDH181	O
.	O

(	O
n	O
=	O
2	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
).	O

(	O
A	O
,	O
B	O
)	O
Breast	O
cancer	O
stem	O
cell	O
(	O
BCSC	O
)	O
populations	O
derived	O
from	O
MCF7	O
and	O
MDA	O
-	O
MB	O
-	O
_231	O
are	O
enriched	O
in	O
NIK	O
.	O

RT	O
-	O
qPCR	O
analysis	O
demonstrated	O
that	O
NIK	O
is	O
mainly	O
expressed	O
in	O
the	O
BCSC	O
population	O
of	O
MCF7	O
(	O
A	O
)	O
(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
)	O
and	O
MDAMB231	O
(	O
B	O
)	O
(	O
n	O
=	O
2	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
)	O
cell	O
lines	O
.	O

To	O
knockdown	O
NIK	O
,	O
two	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
were	O
used	O
in	O
MCF7	O
(	O
C	O
)	O
and	O
MDA	O
-	O
MB231	O
(	O
D	O
)	O
cell	O
lines	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
,	O
*	O
P	O
<	O
0	O
.	O
05	O
).	O

(	O
E	O
)	O
The	O
impact	O
of	O
NIK	O
expression	O
over	O
CSC	O
markers	O
levels	O
was	O
evaluated	O
after	O
stable	O
inhibition	O
of	O
NIK	O
in	O
two	O
independent	O
MCF7	O
replicates	O
.	O

Real	O
Time	O
PCR	O
analysis	O
shows	O
that	O
NIK	O
depletion	O
affects	O
the	O
expression	O
of	O
CSC	O
markers	O
(	O
SOX2	O
,	O
OCT4	O
,	O
ALDH1A3	O
,	O
ALDH8A1	O
).	O

(	O
n	O
=	O
2	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
).	O

(	O
F	O
)	O
Effect	O
of	O
NIK	O
inhibition	O
in	O
two	O
independent	O
MDA	O
-	O
MB	O
-	O
231	O
stable	O
transfected	O
cells	O
lines	O
with	O
shNIK1	O
or	O
shNIK2	O
.	O

RT	O
-	O
qPCR	O
analysis	O
of	O
markers	O
expression	O
after	O
stable	O
NIK	O
inhibition	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

All	O
Real	O
Time	O
PCR	O
were	O
normalized	O
to	O
TBP	O
.	O

The	O
level	O
of	O
CSC	O
markers	O
or	O
NIK	O
was	O
designated	O
to	O
1	O
for	O
MCF7	O
or	O
MDA	O
-	O
MB	O
-	O
231	O
control	O
cells	O
(	O
shLuc	O
).	O

(	O
n	O
=	O
2	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
).	O

(	O
A	O
,	O
B	O
)	O
Frequency	O
of	O
CSCs	O
in	O
MCF7	O
(	O
A	O
)	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
B	O
)	O
depleted	O
NIK	O
cells	O
compared	O
to	O
shLuc	O
cells	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
.,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
C	O
,	O
D	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
CD44	O
(	O
C	O
)	O
and	O
CD24	O
(	O
D	O
)	O
cell	O
surface	O
markers	O
in	O
NIK	O
-	O
deficient	O
stable	O
MCF7	O
cells	O
.	O

(	O
E	O
,	O
F	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
CD44	O
(	O
E	O
)	O
and	O
ESA	O
(	O
F	O
)	O
cell	O
surface	O
markers	O
in	O
NIK	O
-	O
deficient	O
stable	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
and	O
control	O
cells	O
respectively	O
.	O

Images	O
represent	O
an	O
example	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
G	O
)	O
Soft	O
agar	O
clonogenic	O
assays	O
(	O
4	O
,	O
000	O
seeded	O
cells	O
)	O
reveals	O
that	O
stable	O
NIK	O
-	O
deficient	O
cells	O
exhibit	O
a	O
reduced	O
clonogenic	O
ability	O
of	O
MCF7	O
cells	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
.	O

(	O
H	O
)	O
Limited	O
dilution	O
assays	O
showing	O
colonies	O
from	O
three	O
NIK	O
depleted	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
lines	O
grown	O
at	O
low	O
cell	O
density	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
I	O
)	O
Number	O
of	O
spheres	O
formed	O
by	O
three	O
stable	O
NIK	O
-	O
deficient	O
MCF7	O
cell	O
lines	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
J	O
)	O
ELDA	O
analysis	O
showing	O
cancer	O
stem	O
cell	O
frequency	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
deficient	O
-	O
NIK	O
cells	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
control	O
cells	O
xenotransplanted	O
in	O
nude	O
mice	O
.	O

A	O
total	O
of	O
24	O
mice	O
were	O
xenotransplanted	O
with	O
5000	O
(	O
n	O
=	O
5	O
),	O
25000	O
(	O
n	O
=	O
6	O
),	O
100000	O
(	O
n	O
=	O
8	O
)	O
or	O
250000	O
(	O
n	O
=	O
5	O
)	O
cells	O
.	O

MDA	O
-	O
MB	O
-	O
231	O
stable	O
deficient	O
-	O
NIK	O
cells	O
were	O
inoculated	O
into	O
the	O
right	O
flanks	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
control	O
cells	O
in	O
the	O
left	O
flank	O
.	O

Tumors	O
were	O
monitored	O
by	O
bioluminescence	O
.	O

The	O
frequency	O
of	O
cancer	O
stem	O
cells	O
was	O
calculated	O
using	O
ELDA	O
software	O
.	O

(	O
A	O
)	O
RT	O
-	O
qPCR	O
analysis	O
showing	O
increased	O
NIK	O
expression	O
in	O
relation	O
to	O
MCF7	O
control	O
cells	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
B	O
)	O
Expression	O
of	O
CSC	O
markers	O
in	O
three	O
stable	O
NIK	O
-	O
overexpressing	O
MCF7	O
cells	O
.	O

Levels	O
of	O
CSC	O
markers	O
were	O
assessed	O
by	O
RT	O
-	O
qPCR	O
assays	O
and	O
normalized	O
to	O
TBP	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
.,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
C	O
)	O
Frequency	O
of	O
CSCs	O
in	O
MCF7	O
control	O
and	O
MCF7	O
over	O
-	O
expressing	O
cells	O
(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
.,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

Results	O
showed	O
that	O
forced	O
expression	O
of	O
NIK	O
increases	O
the	O
CSC	O
fraction	O
.	O

(	O
D	O
,	O
E	O
)	O
Flow	O
cytometry	O
analysis	O
of	O
CD44	O
(	O
D	O
)	O
or	O
CD24	O
(	O
E	O
)	O
in	O
MCF7	O
overexpressing	O
NIK	O
and	O
MCF7	O
control	O
cells	O
.	O

Images	O
represent	O
an	O
example	O
of	O
three	O
independent	O
experiments	O
.	O

(	O
F	O
)	O
Clonogenic	O
assays	O
showed	O
that	O
forced	O
expression	O
of	O
NIK	O
increase	O
clonogenic	O
ability	O
.	O

Experiments	O
were	O
performed	O
in	O
three	O
independent	O
stable	O
cell	O
clones	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
.,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
G	O
)	O
Quantification	O
of	O
mammosphere	O
number	O
derived	O
from	O
MCF7	O
mock	O
cells	O
(	O
MCF7	O
-	O
Mock	O
)	O
and	O
NIK	O
-	O
overexpressing	O
MCF7	O
cells	O
(	O
MCF7	O
-	O
NIK	O
+)	O
in	O
both	O
first	O
and	O
second	O
passages	O
.	O

For	O
mammosphere	O
assay	O
,	O
2	O
.	O
5	O
×	O
105	O
cells	O
/	O
ml	O
of	O
each	O
cell	O
line	O
were	O
seeded	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
.,	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
H	O
)	O
A	O
total	O
of	O
8	O
mice	O
were	O
xenotransplanted	O
with	O
100000	O
(	O
n	O
=	O
4	O
)	O
and	O
10000	O
(	O
n	O
=	O
4	O
)	O
MCF7	O
overexpressing	O
cells	O
or	O
MCF7	O
control	O
cells	O
.	O

MCF7	O
stable	O
overexpressing	O
-	O
NIK	O
cells	O
were	O
inoculated	O
into	O
the	O
right	O
flanks	O
and	O
MCF7	O
control	O
cells	O
in	O
the	O
left	O
flank	O
.	O

Tumors	O
were	O
monitored	O
each	O
week	O
during	O
120	O
days	O
.	O

The	O
frequency	O
of	O
cancer	O
stem	O
cells	O
was	O
calculated	O
using	O
ELDA	O
software	O
.	O

.	O

(	O
A	O
)	O
Reporter	O
gene	O
assay	O
showing	O
the	O
effects	O
of	O
NIK	O
overexpression	O
over	O
NF	O
-	O
κB	O
activity	O
under	O
basal	O
conditions	O
.	O

Assays	O
were	O
performed	O
in	O
MCF7	O
cells	O
transiently	O
transfected	O
with	O
control	O
or	O
NIK	O
expression	O
vector	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
.).	O

(	O
B	O
)	O
Reporter	O
gene	O
assay	O
showing	O
the	O
effects	O
of	O
NIK	O
depletion	O
on	O
NF	O
-	O
κB	O
activity	O
.	O

Assays	O
were	O
performed	O
in	O
an	O
MCF7	O
stable	O
cell	O
line	O
bearing	O
an	O
NF	O
-	O
κB	O
reporter	O
vector	O
.	O

Stable	O
cells	O
were	O
transiently	O
transfected	O
to	O
inhibit	O
NIK	O
.	O

NF	O
-	O
κB	O
activity	O
was	O
calculated	O
as	O
fold	O
difference	O
between	O
control	O
and	O
NIK	O
-	O
silenced	O
cells	O
.	O

(	O
n	O
=	O
4	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
e	O
.	O
m	O
.	O
*	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
C	O
)	O
Western	O
blot	O
of	O
NF	O
-	O
κB	O
molecules	O
in	O
MCF7	O
enriched	O
NIK	O
and	O
in	O
MCF7	O
control	O
cells	O
.	O

GAPDH	O
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
D	O
)	O
Densitometric	O
scans	O
from	O
three	O
independent	O
assays	O
were	O
quantified	O
,	O
normalized	O
to	O
GAPDH	O
and	O
calculated	O
as	O
fold	O
difference	O
.	O

(	O
E	O
–	O
J	O
)	O
Immunofluorescence	O
analysis	O
of	O
p52	O
(	O
E	O
),	O
RelB	O
(	O
F	O
),	O
p50	O
(	O
G	O
),	O
p65	O
(	O
H	O
),	O
phospho	O
-	O
P52	O
(	O
I	O
)	O
and	O
phosphor	O
-	O
P65	O
(	O
J	O
)	O
in	O
MCF7	O
cells	O
transiently	O
overexpressing	O
NIK	O
and	O
MCF7	O
control	O
cells	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
proteins	O
were	O
stained	O
with	O
Cy3	O
-	O
conjugated	O
secondary	O
antibody	O
and	O
nuclei	O
were	O
stained	O
with	O
4	O
′-	O
6	O
-	O
Diamidino	O
-	O
2	O
-	O
phenolindole	O
(	O
DAPI	O
).	O

Photographs	O
are	O
representative	O
of	O
three	O
independent	O
experiments	O
.	O

Images	O
for	O
immunofluorescence	O
staining	O
were	O
taken	O
using	O
an	O
x	O
63	O
oil	O
lens	O
.	O

(	O
A	O
)	O
Pie	O
chart	O
showing	O
the	O
percentage	O
of	O
HER2	O
,	O
Luminal	O
,	O
and	O
Triple	O
Negative	O
breast	O
cancer	O
samples	O
(	O
n	O
=	O
191	O
).	O

(	O
B	O
)	O
Percentage	O
of	O
cells	O
expressing	O
NIK	O
in	O
HER2	O
,	O
Luminal	O
,	O
and	O
Triple	O
Negative	O
breast	O
tumors	O
.	O

NIK	O
expression	O
is	O
higher	O
in	O
HER2	O
breast	O
tumors	O
(	O
p	O
=	O
0	O
.	O
01	O
).	O

(	O
C	O
)	O
Percentage	O
of	O
cells	O
expressing	O
NIK	O
in	O
tumors	O
with	O
different	O
expression	O
levels	O
of	O
HER2	O
(	O
0	O
=	O
absent	O
;	O
1	O
=	O
weak	O
;	O
2	O
=	O
moderate	O
;	O
3	O
=	O
strong	O
).	O

NIK	O
expression	O
is	O
higher	O
in	O
tumors	O
with	O
strong	O
expression	O
of	O
HER2	O
(	O
p	O
=	O
0	O
.	O
005	O
).	O

(	O
D	O
)	O
Pie	O
chart	O
showing	O
the	O
percentage	O
of	O
Grades	O
I	O
,	O
II	O
,	O
and	O
III	O
breast	O
cancer	O
tissues	O
(	O
n	O
=	O
191	O
).	O

(	O
E	O
)	O
Percentage	O
of	O
cells	O
expressing	O
NIK	O
in	O
Grade	O
I	O
,	O
II	O
and	O
III	O
tumors	O
.	O

NIK	O
expression	O
levels	O
increase	O
in	O
Grade	O
III	O
tumor	O
(	O
p	O
=	O
0	O
.	O
07	O
).	O

(	O
A	O
)	O
Percentage	O
of	O
Nuclear	O
factor	O
-	O
kappa	O
B	O
-	O
inducing	O
kinase	O
(	O
NIK	O
)-	O
positive	O
breast	O
tissues	O
.	O

(	O
B	O
)	O
Percentage	O
of	O
ALDH	O
positive	O
breast	O
tissues	O
.	O

(	O
C	O
)	O
Venn	O
diagram	O
showing	O
breast	O
cancer	O
tissues	O
expressing	O
both	O
NIK	O
and	O
ALDH	O
protein	O
.	O

(	O
D	O
–	O
H	O
)	O
Immunohistochemistry	O
of	O
NIK	O
and	O
Aldehyde	O
dehydrogenase	O
(	O
ALDH	O
)	O
expression	O
.	O

NIK	O
-	O
positive	O
cells	O
are	O
brown	O
based	O
on	O
DAB	O
chromogen	O
,	O
and	O
ALDH	O
-	O
positive	O
cells	O
are	O
pink	O
based	O
on	O
Fast	O
Red	O
chromogen	O
.	O

Nuclei	O
are	O
stained	O
with	O
hematoxylin	O
(	O
blue	O
).	O

The	O
second	O
column	O
represents	O
an	O
enlargement	O
of	O
the	O
area	O
denoted	O
by	O
box	O
in	O
the	O
adjacent	O
left	O
panel	O
showing	O
fine	O
cellular	O
details	O
of	O
immunohistochemistry	O
.	O

(	O
D	O
)	O
Graph	O
showing	O
percentage	O
of	O
tissues	O
having	O
cellular	O
colocalization	O
in	O
Breast	O
Cancer	O
samples	O
expressing	O
both	O
NIK	O
and	O
ALDH	O
.	O

(	O
E	O
)	O
Representation	O
of	O
breast	O
tumors	O
(	O
n	O
=	O
93	O
)	O
expressing	O
ALDH	O
and	O
NIK	O
in	O
the	O
same	O
cells	O
.	O

(	O
F	O
)	O
Immunohistochemistry	O
of	O
breast	O
tumors	O
showing	O
NIK	O
and	O
ALDH	O
expression	O
in	O
different	O
cells	O
(	O
n	O
=	O
10	O
).	O

(	O
A	O
)	O
Principal	O
component	O
analysis	O
of	O
gene	O
expression	O
profiles	O
for	O
high	O
NIK	O
-	O
expressing	O
MCF7	O
cells	O
,	O
low	O
NIK	O
-	O
expressing	O
MCF7	O
cells	O
and	O
MCF7	O
control	O
cells	O
.	O

(	O
B	O
)	O
Clustering	O
diagram	O
of	O
samples	O
and	O
differentially	O
expressed	O
genes	O
in	O
MCF7	O
cells	O
overexpressing	O
NIK	O
and	O
NIK	O
-	O
deficient	O
MCF7	O
cells	O
.	O

Log	O
-	O
Fold	O
Changes	O
of	O
differentially	O
expressed	O
genes	O
are	O
depicted	O
in	O
a	O
heat	O
map	O
,	O
scaling	O
from	O
low	O
(	O
green	O
)	O
to	O
high	O
(	O
red	O
).	O

Experiments	O
were	O
performed	O
in	O
three	O
independent	O
transiently	O
-	O
transfected	O
MCF7	O
cell	O
lines	O
(	O
C	O
).	O

Graph	O
showing	O
the	O
fold	O
change	O
of	O
stem	O
cells	O
-	O
associated	O
genes	O
in	O
high	O
NIK	O
-	O
expressing	O
cells	O
and	O
(	O
D	O
)	O
low	O
NIK	O
-	O
expressing	O
cells	O
.	O

(	O
E	O
)	O
RT	O
-	O
qPCR	O
analysis	O
of	O
EGR1	O
,	O
TCN1	O
,	O
DUSP6	O
,	O
GDF15	O
,	O
CSPG4	O
and	O
MAP2K6	O
in	O
MCF7	O
overexpressing	O
-	O
NIK	O
cells	O
,	O
MCF7	O
control	O
cells	O
,	O
NIK	O
-	O
deficient	O
MCF7	O
cells	O
(	O
shNIK1	O
and	O
shNIK2	O
)	O
and	O
MCF7	O
control	O
cells	O
(	O
shLuc	O
).	O

All	O
RT	O
-	O
qPCR	O
were	O
normalized	O
to	O
TBP	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
+/−	O
s	O
.	O
d	O
,	O
p	O
<	O
0	O
.	O
05	O
).	O

(	O
G	O
)	O
IPA	O
network	O
of	O
top	O
gene	O
networks	O
from	O
NIK	O
-	O
overexpressing	O
cells	O
.	O

(	O
H	O
)	O
IPA	O
network	O
of	O
top	O
gene	O
networks	O
from	O
NIK	O
-	O
depleted	O
cells	O
.	O

Note	O
that	O
ERK1	O
/	O
2	O
is	O
a	O
central	O
node	O
in	O
both	O
networks	O
.	O

Red	O
color	O
indicates	O
induced	O
genes	O
and	O
green	O
color	O
represents	O
suppressed	O
genes	O
.	O

(	O
A	O
)	O
Western	O
Blot	O
analysis	O
of	O
phospho	O
-	O
ERK1	O
/	O
2	O
in	O
MCF7	O
transiently	O
expressing	O
NIK	O
,	O
control	O
vector	O
or	O
NIK	O
knock	O
-	O
down	O
cells	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
d	O
.,	O
p	O
*	O
<	O
0	O
.	O
03	O
).	O

(	O
B	O
)	O
Relative	O
expression	O
of	O
target	O
genes	O
in	O
MCF7	O
cells	O
treated	O
with	O
30	O
uM	O
FR180204	O
or	O
an	O
equivalent	O
amount	O
of	O
DMSO	O
during	O
24	O
hrs	O
.	O

The	O
lower	O
image	O
represents	O
the	O
effect	O
of	O
FR180204	O
on	O
ERK1	O
/	O
2	O
inhibition	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
d	O
.,	O
*	O
p	O
<	O
0	O
.	O
05	O
)	O
(	O
C	O
)	O
Relative	O
expression	O
of	O
target	O
genes	O
in	O
MCF7	O
transiently	O
overexpressing	O
NIK	O
cells	O
cultured	O
with	O
30	O
μM	O
FR180204	O
or	O
DMSO	O
for	O
24	O
hrs	O
.	O

(	O
n	O
=	O
2	O
,	O
error	O
bars	O
are	O
s	O
.	O
e	O
.	O
m	O
)	O
(	O
D	O
)	O
Frequency	O
of	O
CSCs	O
in	O
MCF7	O
control	O
and	O
MCF7	O
over	O
-	O
expressing	O
cells	O
cultured	O
with	O
30	O
uM	O
FR180204	O
or	O
DMSO	O
during	O
24	O
hr	O
.	O

(	O
n	O
=	O
3	O
,	O
error	O
bars	O
are	O
s	O
.	O
d	O
.,	O
*	O
p	O
<	O
0	O
.	O
04	O
).	O

